documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registranttable contents gilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item reserved part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences truvada viread hepsera ambisome emtriva vistide letairis volibris ranexa cayston atripla registered trademark belonging bristolmyers squibb gilead sciences llc lexiscan registered trademark belonging astellas us llc macugen registered trademark belonging eyetech inc sustiva registered trademark bristolmyers squibb pharma company tamiflu registered trademark belonging hoffmannla roche inc report also includes trademarks service marks trade names companiestable contents annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forward looking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forwardlooking statements various reasons including identified risk factors beginning given risks uncertainties cautioned place undue reliance forward looking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise table contents part item business overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia date focused efforts bringing novel therapeutics treatment life threatening diseases market continue seek add existing portfolio products internal discovery clinical development programs active product acquisition inlicensing strategy acquired cv therapeutics inc cv therapeutics publiclyheld biopharmaceutical company based palo alto california primarily focused discovery development commercialization small molecule drugs treatment cardiovascular diseases cv therapeutics two marketed products ranexa ranolazine lexiscan regadenoson well several product candidates clinical development treatment cardiovascular metabolic pulmonary diseases products truvada emtricitabine tenofovir disoproxil fumarate oral formulation dosed day part combination therapy treat human immunodeficiency virus hiv infection adults fixeddose combination antihiv medications viread tenofovir disoproxil fumarate emtriva emtricitabine atripla efavirenz mg emtricitabine mg tenofovir disoproxil fumarate mg oral formulation dosed day treatment hiv infection adults atripla first daily single tablet regimen hiv intended stand alone therapy combination antiretrovirals fixeddose combination antihiv medications viread emtriva bristol myerssquibb companys nonnucleoside reverse transcriptase inhibitor sustiva efavirenz viread oral formulation nucleotide analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults received marketing approval viread treatment chronic hepatitis b licensed glaxosmithkline inc gsk rights commercialize viread treatment chronic hepatitis b china emtriva oral formulation nucleoside analogue reverse transcriptase inhibitor dosed day part combination therapy treat hiv infection adults united states europe emtriva also approved part combination therapy treat hiv infection children hepsera adefovir dipivoxil oral formulation nucleotide analogue polymerase inhibitor dosed day treat chronic hepatitis b licensed gsk rights commercialize hepsera treatment chronic hepatitis b asia latin america certain territories ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat serious invasive fungal infections caused various fungal species corporate partner astellas pharma us inc promotes sells ambisome united states canada promote sell ambisome europe australia new zealand letairis ambrisentan endothelin receptor antagonist era indicated treatment pulmonary arterial hypertension pah group patients class ii iii symptoms improve exercise capacity delay clinical worsening sublicensed gsk rights ambrisentan marketed gsk volibris ambrisentan pah territories outside united states table contents ranexa indicated treatment chronic angina licensed menarini international operations luxembourg sa rights ranexa territories outside united states vistide cidofovir injection antiviral medication treatment cytomegalovirus retinitis patients aids cayston aztreonam inhalation solution inhaled antibiotic treatment improve respiratory systems cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa september received conditional marketing approval cayston europe canada february received marketing approval cayston united states following table lists aggregate product sales major products thousands total total total product product product sales sales sales antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis ranexa total product sales see item note consolidated financial statements included annual report total revenues geographic area royalties products tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approved treatment influenza children adults countries including united states japan european union tamiflu also approved prevention influenza children adults united states japan european union developed tamiflu f hoffmannla roche ltd together hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us royalties based percentage net sales tamiflu macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelated macular degeneration macugen developed eyetech inc eyetech using technology licensed us promoted united states eyetech eyetech holds exclusive rights manufacture sell macugen united states pfizer inc pfizer holds exclusive right manufacture sell macugen rest world receive royalties eyetech based sales macugen worldwide lexiscan injection indicated use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi test detects characterizes coronary artery disease patients unable undergo adequate exercise stress astellas us llc exclusive rights manufacture table contents sell lexiscan united states subject obligations pay us royalties based sales lexiscan united states may marketing authorization application regadenoson mpi european union validated european medicines agency commercialization distribution us international commercial sales operations marketing subsidiaries australia austria belgium canada denmark finland france germany greece ireland italy netherlands new zealand norway portugal spain sweden switzerland turkey united kingdom united states products marketed commercial teams andor conjunction third party distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant third party distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory united states commercial team promotes truvada viread emtriva hepsera letairis ranexa promote atripla united states joint venture partner bristol myerssquibb company bms distribute truvada atripla viread emtriva hepsera vistide ranexa united states exclusively wholesale channel product sales three large wholesalers cardinal health inc mckesson corp amerisourcebergen corp accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total revenues corporate partner astellas promotes sells distributes ambisome lexiscan us united states cayston letairis distributed exclusively specialty pharmacies specialty pharmacies specialize dispensing medications complex chronic conditions may require high level patient education ongoing counseling sell distribute truvada viread emtriva hepsera ambisome asia australia europe latin america middle east new zealand either commercial teams third party distributors corporate partners promote atripla jointly bms majority countries europe responsible selling distributing product countries limited number central eastern european countries either gilead bms third party distributor sole promoting selling distributing company agreement merck co inc merck promote distribute atripla countries latin america asiapacific either merck existing third party distributors gsk promotes sells distributes hepsera asia latin america certain territories plans promote sell distribute viread treatment chronic hepatitis b china rely corporate partner japan tobacco inc promote sell truvada viread emtriva japan corporate partner astellas promotes sells distributes ambisome canada dainippon sumitomo pharma co ltd responsible promotion distribution ambisome japan access developing world gilead access program established certain hiv products available substantially reduced prices countries developing world developed system tiered pricing reflects economic status using gross national incomegniper capita hiv prevalence approach allows us price therapies based countrys ability pay example higher hiv prevalence exists certain country country also relatively high gni country would moved lower price tier accommodate higher burden disease table contents also support many clinical studies donation products help define best treatment strategies developing world countries example november entered collaborative agreement medical research council mrc united kingdom boehringer ingelheim gmbh gsk connection clinical study conducted mrc antiretroviral hiv therapy africa trial called dart development antiretroviral therapy study aimed studying clinical versus laboratory monitoring practices structured treatment interruptions continuous antiretroviral therapy adults hiv infection subsaharan africa provide viread cost dart study also work closely world health organization nongovernmental organizations provide ambisome treatment leishmaniasis parasitic disease preferential price resource limited settings support numerous clinical studies investigating role ambisome treat visceral cutaneous leishmaniasis developing countries collaborations organizations drugs neglected diseases initiative mdecins sans frontires also entered number collaborations related access products developing world include pharmachem technologies grand bahama ltd pharmachem pharmachem one manufacturing partners established facility bahamas manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla resource limited countries cooperative effort pharmachem grand bahama port authority aspen pharmacare holdings ltd aspen october entered nonexclusive manufacturing distribution agreement aspen providing manufacture distribution viread truvada treatment hiv infection certain developing world countries included gilead access program november amended agreement aspen amended agreement aspen retained right manufacture distribute viread truvada treatment hiv infection developing world countries aspen right purchase viread truvada unlabeled bottles us distribution countries also right manufacture viread truvada using active pharmaceutical ingredient purchased aspen suppliers approved us aspen also granted right manufacture distribute generic versions emtricitabine tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination emtricitabine treatment hiv infection aspen required pay us royalties net sales viread truvada well royalties net sales generic versions tenofovir disoproxil fumarate including versions tenofovir disoproxil fumarate combination generic versions emtricitabine manufactured distributed aspen generic licenses entered nonexclusive license agreements thirteen indian generic manufacturers granting rights produce distribute generic versions tenofovir disoproxil fumarate treatment hiv infection low income countries around world includes india many low income countries gilead access program agreements require generic manufacturers meet certain national international regulatory standards include technology transfers enable expeditious production large volumes high quality generic versions tenofovir disoproxil fumarate addition agreements allow manufacture commercial quantities active pharmaceutical ingredient finished product merck co inc merck august entered agreement affiliate merck pursuant gilead merck provide atripla substantially reduced prices hiv infected patients developing countries africa caribbean latin america southeast asia agreement manufacture atripla using efavirenz supplied merck merck handles distribution product countries covered agreement table contents international partnership microbicides ipm conrad december entered agreement granted rights ipm conrad cooperating agency us agency international development committed improving reproductive health expanding contraceptive choices women men develop manufacture proven efficacious arrange distribution resource limited countries certain formulations tenofovir use topical microbicide prevent hiv infection competition products development programs target number areas including viral fungal respiratory cardiovascular diseases many commercially available products treatment diseases many companies institutions making substantial investments developing additional products treat diseases products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance patent protection ease use price insurance reimbursement coverage distribution marketing hiv products hiv landscape becoming competitive complex treatment trends continue evolve growing number antihiv drugs currently sold advanced stages clinical development approximately branded hiv drugs available united states products primarily compete fixeddose combination products nucleotidenucleoside reverse transcriptase inhibitors nrti class including combivir lamivudinezidovudine epzicomkivexa abacavirlamivudine trizivir abacavirlamivudinezidovudine sold joint venture established november gsk pfizer focused hiv therapies hiv products compete directly products nrti class sold bms although hiv products also compete broadly hiv products abbott laboratories inc boehringer ingelheim gmbh merck pfizer roche tibotec therapeutics bmss videx ec didanosine ddi became first generic hiv product united states gsks retrovir zidovudine also faces generic competition united states result launch generic zidovudine bmss zerit stavudine also faces generic competition united states result launch generic stavudine date little impact generic didanosine zidovudine stavudine price hiv products however price decreases hiv products may result longer term may compound patent covering epivir lamivudine expire lamivudine marketed joint venture established gsk pfizer competitive emtricitabine active pharmaceutical ingredient emtriva component truvada atripla certain third party payors plans may use entry generic lamivudine reason exert pricing pressure hiv products table contents ambisome ambisome faces strong competition several current expected competitors competition current expected competitors may erode revenues receive sales ambisome ambisome faces competition vfend voriconazole developed pfizer caspofungin product developed merck marketed cancidas united states caspofungin elsewhere ambisome also competes lipidbased amphotericin b products including abelcet amphotericin b lipid complex injection sold enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sold three rivers pharmaceuticals llc worldwide anfogen amphotericin b liposomal sold genpharma sa argentina bms numerous generic manufacturers sell conventional amphotericin b also competes ambisome aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association hbv products hepatitis b virus hbv products hepsera viread face significant competition existing expected therapies treating patients chronic hepatitis b hbv products face competition baraclude entecavir oral nucleoside analogue developed bms launched united states tyzekasebivo telbivudine oral nucleoside analogue developed novartis pharmaceuticals corporation novartis sale united states european union china hbv products also compete epivirhbvzeffix lamivudine developed gsk collaboration shire pharmaceuticals group plc sold major countries throughout north south america europe asia hepsera viread treatment chronic hepatitis b also compete established immunomodulatory therapies including introna interferon alfab sold schering plough corporation major countries throughout north south america europe asia pegasys pegylated interferon alfaa injectable drug similar introna sold roche treatment chronic hepatitis b letairis letairis competes directly tracleer bosentan sold actelion pharmaceuticals us inc actelion indirectly pah products united therapeutics corporation pfizer ranexa ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates addition surgical treatments interventions coronary artery bypass grafting percutaneous coronary intervention another option angina patients may perceived healthcare practitioners preferred methods treat cardiovascular disease underlies causes angina vistide vistide competes number drugs also treat cytomegalovirus retinitis including cytovene iv cytovene ganciclovir sold intravenous oral formulations roche ocular implant bausch lomb incorporated valcyte valganciclovir also marketed roche foscavir foscarnet intravenous drug sold astrazeneca plc vitravene fomivirsen drug injected directly eye sold cibavision cayston cayston competes primarily tobi tobramycin inhalation solution usp inhaled medication sold novartis treatment cf patients whose lungs contain p aeruginosa tamiflu tamiflu competes relenza zanamivir antiinfluenza drug sold gsk relenza neuraminidase inhibitor delivered orallyinhaled dry powder generic competitors include table contents amantadine rimantadine oral tablets inhibit replication influenza virus biocryst pharmaceuticals inc developing injectable formulations peramivir influenza neuraminidase inhibitor treatment influenza currently phase clinical trials macugen macugen competes primarily visudyne verteporfin injection sold novartis used connection photodynamic therapy lucentis ranibizumab sold genentech inc lexiscan united states numerous marketed generic andor branded pharmacologic stress agents compete lexiscan clinical data inc developing apadenoson pharmacologic stress agent mpi currently phase clinical trials king pharmaceuticals inc developing binodenoson pharmacologic stress agent currently phase clinical trials product candidates could also compete lexiscan number companies pursuing development technologies competitive research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs collaborative relationships part business strategy establish collaborations companies universities medical research institutions assist clinical development andor commercialization certain products product candidates provide support research programs also evaluate opportunities acquiring products rights products technologies complementary business companies universities medical research institutions information regarding certain relationships including ongoing financial accounting impact business found item note consolidated financial statements included annual report commercial collaborations although currently number collaborations corporate partners govern manufacture sale distribution andor marketing products various territories worldwide following commercial collaborations significant us financial statement perspective significant ongoing collaboration activity exists bristolmyers squibb company bms december entered collaboration bms develop commercialize single tablet regimen truvada bmss sustiva united states combination approved use united states july sold brand name atripla bms structured collaboration joint venture forming limited liability company called bristolmyers squibb gilead sciences llc terms collaboration bms granted royalty free sublicenses joint venture use respective company owned technologies return granted license joint venture use intellectual property results collaboration economic interests joint venture held us bms including share revenues outofpocket expenses based portion net selling price atripla attributable truvada sustiva respectively since net selling price truvada may change time relative net selling price sustiva bmss respective economic interests joint venture may vary annually bms share marketing sales efforts parties providing equivalent sales force efforts levels agreed annually bms us daily operations joint venture governed four primary joint committees formed bms us responsible accounting financial reporting tax table contents reporting product distribution joint venture september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada agreement continue terminated mutual agreement parties addition either party may terminate partys participation collaboration within days launch least one generic version partys single agent products double agent products nonterminated party right continue sell atripla shortterm obligation pay royalties terminated party december entered collaboration bms sets forth terms conditions bms commercialize atripla european union iceland liechtenstein norway switzerland either bms third party distributor act selling party countries responsible among things receiving processing customer orders warehousing product collecting receivables handling returns manufacturing atripla coordinated us primarily responsible distribution logistics general parties share revenues outofpocket expenses proportion net selling prices truvada respect us efavirenz respect bms agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european countries covered agreement prior time either party may terminate agreement reason termination effective december nonterminating party right continue sell atripla obligated pay terminating party certain royalties three year period following effective date termination event nonterminating party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier f hoffmannla roche ltd together hoffmannla roche inc roche september entered development license agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche original agreement roche exclusive right obligation manufacture sell tamiflu worldwide subject obligation pay us percentage net sales roche generated tamiflu sales agreement received upfront payment amount million entitled receive additional milestone payments million upon achievement certain development regulatory objectives received milestone payments october roche also made cash payment us amount million related reimbursement certain research preclinical development expenses obligation prosecute maintain certain patents agreement november entered first amendment supplement original agreement roche amendment eliminated cost goods adjustments royalty calculation retroactive calendar year future calculations amendment also provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis committees consists representatives roche us amendment option provide specialized sales force supplement roches us marketing efforts tamiflu exercised date agreement roches obligation pay royalties us terminate countrybycountry basis patents providing exclusivity tamiflu countries expire roche may terminate agreement reason case rights tamiflu would revert us either party may terminate agreement response material breach party glaxosmithkline inc gsk march sublicensed gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis marketed name table contents volibris territories outside united states pah territories outside united states license agreement received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million december received million potential milestone payments addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development agreement gsks obligation pay royalties us terminate countrybycountry basis earlier date generic equivalents sold country achieve certain percentage total prescriptions product plus generic equivalents fifteenth anniversary commercial launch country gsk may terminate agreement reason upon termination rights product would revert us either party may terminate agreement response material breach party research collaborations currently number collaborations corporate partners govern research development rd certain compounds drug candidates following research collaborations significant us financial statement perspective significant ongoing collaboration activity exists japan tobacco inc japan tobacco march entered licensing agreement japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco would retain rights agreement responsible seeking regulatory approval territories required use diligent efforts commercialize product treatment hiv infection bear costs expenses associated commercialization efforts terms agreement paid upfront license fee million obligated make total potential milestone payments million upon achievement certain clinical regulatory commercial objectives additionally obligated pay royalties based net sales territories market product december made total milestone payments million agreement obligation pay royalties japan tobacco terminate productbyproduct basis patents providing exclusivity product expire later tenth anniversary commercial launch product may terminate agreement reason case license granted japan tobacco us would terminate either party may terminate agreement response material breach party tibotec pharmaceuticals tibotec july entered license collaboration agreement tibotec whollyowned subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trials agreement tibotec granted us exclusive license combination product administration adults daily oral dosage form worldwide excluding developing world countries japan neither party restricted combining drugs drugs pay tibotec million tibotecs development costs tmc required use commercially reasonable efforts develop formulate combination product including table contents completion bioequivalence studies year ended december recorded million reimbursable rd expenses incurred tibotec development tmc tibotec required use commercially reasonable efforts develop tmc obtain approval united states europe manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product licensed countries tibotec right detail combination product licensed countries option request distributor combination product limited number countries price combination product expected sum price truvada price tmc purchased separately cost tmc purchased us tibotec combination product approximate market price tmc less specified percentage thirty percent either party may terminate agreement combination product withdrawn market party materially breaches agreement certain clinical regulatory conditions met may terminate agreement united states canada expiration lasttoexpire patent tenofovir disoproxil fumarate united states may terminate agreement country expiration lasttoexpire patent tenofovir disoproxil fumarate country european union tibotec may terminate agreement united states canada expiration lasttoexpire patent tmc united states may terminate agreement country expiration lasttoexpire patent tmc country european union research development addition entering collaborations companies universities medical research institutions seek add existing portfolio products internal discovery clinical development programs active inlicensing product acquisition strategy acquisitions myogen inc corus pharma inc acquired navitas assets llcs assets related cicletanine business evaluating potential treatment pah acquired cv therapeutics expand cardiovascular therapeutic area research scientists foster city palo alto san dimas california durham north carolina seattle washington engaged discovery development new molecules technologies hope lead new medicines novel formulations existing drugs product development efforts cover wide range medical conditions including hivaids liver disease cardiovascular disease respiratory disease summary key product candidates corresponding current stages development additional information development pipeline visit website wwwgileadcom product candidate description marketing application pending regadenoson may marketing authorization application regadenoson use pharmacologic stress agent radionuclide mpi european union validated european medicines agency phase ambrisentan ambrisentan oral endothelin receptor antagonist also evaluated treatment idiopathic pulmonary fibrosis ipf pulmonary hypertension secondary ipf table contents product candidate description elvitegravir elvitegravir oral integrase inhibitor evaluated part combination therapy hiv treatment experienced patients combination truvada tmc combination tenofovir disoproxil fumarate emtricitabine tmc evaluation treatment hivaids treatmentnaive patients formulation work underway develop oncedaily fixeddose regimen three compounds phase aztreonam inhalation solution aztreonam inhalation solution also evaluated treatment bronchiectasis cicletanine cicletanine oral agent evaluation treatment pah cobicistat formerly gs cobicistat pharmacoenhancer evaluation boosting agent certain hiv medicines antiretrovirals fixeddose combination elvitegravir cobicistat oncedaily fixeddose quad regimen elvitegravir cobicistat tenofovir disoproxil fumarate truvada emtricitabine evaluation treatment hivaids treatmentnave patients gs gs oral nonnucleoside polymerase inhibitor evaluated treatment hepatitis c gs gs inhaled coformulation fosfomycin tobramycin evaluation treatment bacterial infections associated cf gs gs oral caspase inhibitor evaluation treatment hepatitis c nonalcoholic steatohepatitis preparing phase ranolazine ranolazine late sodium current inhibitor also going evaluated treatment diastolic heart failure patients preserved ejection fraction phase gs gs ab adenosine antagonist evaluation treatment pulmonary diseases gs gs novel protease inhibitor evaluated treatment hepatitis c gs gs oral epithelial sodium channel blocker designed increase airway hydration patients pulmonary disease gs gs partial adenosine antagonist evaluation treatment diabetes hypertriglyceridemia total rd expenses million compared million million patents proprietary rights patents proprietary rights important business properly designed enforceable patent difficult competitors use technology create competitive table contents products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology also rely trade secrets internal knowhow technological innovations agreements third parties develop maintain protect competitive position ability competitive depend success strategy number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows actual estimated expiration dates united states europe primary patents patents may issue pending applications cover compounds marketed products us patent european patent products expiration expiration vistide hepsera letairis ambisome tamiflu macugen viread ranexa lexiscan emtriva truvada atripla cayston supplementary protection certificate spc protection obtained certain european countries confers auxiliary form patent exclusivity spc protection obtained certain european countries confers auxiliary form patent exclusivity patent term extension applied spc applied upon marketing approval european union based european patent expiration date viread one components truvada based european patent expiration date viread one components atripla application pending patents covering active pharmaceutical ingredients truvada atripla viread emtriva hepsera letairis vistide lexiscan held third parties acquired exclusive rights patents agreements parties patents cover ranolazine active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome instead hold patents liposomal formulations compound also protect formulations trade secrets addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera applications pending various countries asia including china relate specific forms table contents formulations hepsera asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years obtain marketing approval products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions example extensions patents many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain also important infringe patents proprietary rights others violate agreements grant proprietary rights us infringe patents violate agreements could prevented developing selling products using processes covered patents agreements could required obtain license third parties allow us use technology certain required could obtain license third party technology could obtain one reasonable cost able obtain required license alternative technologies may unable develop commercialize products business could adversely affected example aware body patents may relate operation letairis education access program leap restricted distribution program designed support letairis addition actelion markets tracleer applied patent claims method use eras treatment ipf issued patent may interfere efforts commercialize era ambrisentan ipf patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected participation events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation examination proceedings regarding enforcement validity existing patents future patents could invalidate patents substantially reduce protection example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil tenofovir disoproxil fumarate active pharmaceutical ingredient truvada atripla viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto office actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us within brazilian patent authority filed civil action brazilian federal court table contents appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil brazilian government purchased approximately million hiv products anticipate purchases hiv products brazilian government similar level another example patent office india initially allowed claims covering tenofovir disoproxil tenofovir disoproxil fumarate however indian civil procedure prior official grant allowed applications several parties filed legal actions protest decision grant patents august indian patent office announced decided actions us would therefore allow patents granted filed appeal within indian patent office applications predict outcome proceedings unable successfully appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unable successfully appeal negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate could reduce amount royalties receive indian generic licenses pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries africa asia including china permit enforcement patents third party manufacturers able sell generic versions products countries part approval process products us food drug administration fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully example november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva us district court new york infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir patents protecting viread january also received notices teva amending andas related truvada atripla notice related truvada teva challenged four patents related tenofovir two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir two additional patents related table contents emtricitabine two patents related efavirenz expect file lawsuit teva infringement four viread patents two additional emtricitabine patents bms merck rights enforce defend patents related efavirenz predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection truvada atripla viread united states could substantially shortened patents covering products invalidated fda could approve tevas request manufacture generic version products also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions manufacturing raw materials manufacturing strategy contract third parties manufacture majority solid dose products also rely corporate partners manufacture certain products additionally manufacturing facilities san dimas california edmonton alberta canada cork ireland manufacture certain products active pharmaceutical ingredients clinical commercial uses contract third parties manufacture certain products clinical commercial purposes including truvada atripla viread emtriva hepsera ranexa vistide cayston use multiple third party contract manufacturers manufacture tenofovir disoproxil fumarate active pharmaceutical ingredient viread one active pharmaceutical ingredients truvada atripla emtricitabine active pharmaceutical ingredient emtriva one active pharmaceutical ingredients truvada atripla rely single third party manufacturer manufacture active pharmaceutical ingredients vistide ranexa cayston diluent cayston also manufactured single manufacturer single site also rely third party contract manufacturers tablet capsulate products example use multiple third party contract manufacturers tablet truvada atripla viread hepsera ranexa emtriva capsulation also completed third party contract manufacturers rely single third party supplier tablet emtriva letairis also manufacturing agreements many corporate partners roche third parties responsible manufacturing tamiflu agreement roche joint manufacturing committee composed representatives roche us opportunity review roches existing manufacturing capacity tamiflu global plans manufacturing tamiflu astellas corporate partner lexiscan america responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan pari pharma gmbh responsible manufacturing device required administer cayston lungs patients device made single supplier single site san dimas facility manufacture fill package products manufacture ambisome cayston exclusively facility depend single supplier high quality cholesterol used table contents manufacture ambisome fill finish macugen exclusively facilities san dimas manufacturing agreements eyetech pfizer eyetech currently provides us pegaptanib sodium active pharmaceutical ingredient macugen also fill package drug product truvada atripla viread emtriva hepsera ranexa finished forms facilities san dimas edmonton alberta facility carry process research scaleup clinical development candidates manufacture active pharmaceutical ingredients investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes addition utilize site manufacture emtricitabine also manufacture active pharmaceutical ingredients letairis hepsera exclusively edmonton site although another supplier qualified make active pharmaceutical ingredient letairis fill package drug product truvada atripla viread emtriva cayston hepsera finished forms facilities cork ireland also perform quality control testing final labeling packaging ambisome distribution many products european union elsewhere facility utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral products well product packaging activities manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations third party manufacturers corporate partners subject fdas current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally third party manufacturers corporate partners independent entities subject unique operational financial risks control third party manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected believe technology use manufacture products proprietary products manufactured third party contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements third party manufacturers intended restrict manufacturers using revealing technology certain third party manufacturers comply restrictions addition third party manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements third party manufacturers want use technology allow another manufacturer use technology third party manufacturer could refuse allow us use technology could demand terms use technology acceptable us need access certain supplies products manufacture products delivery material suppliers interrupted reason unable purchase sufficient quantities raw materials used manufacture products may unable ship certain products commercial supply supply product candidates development clinical trials addition products materials utilize operations made one facility example manufacture ambisome cayston fill finish macugen exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome cayston macugen meet market needs problems single suppliers depend may negatively impact development commercialization efforts table contents future products continue consider developing additional manufacturing capabilities establishing additional third party suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale unable develop manufacturing capabilities internally contract large scale manufacturing third parties acceptable terms future products ability conduct large scale clinical trials meet customer demand commercial products adversely affected seasonal operations backlog worldwide product sales reflect significant degree seasonality however royalty revenues represented total revenues consisted primarily tamiflu royalties affected seasonality royalty revenue recognize roches sales tamiflu impacted severity flu seasons product delivery response hn influenza pandemic part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states countries united states drugs subject rigorous fda regulation federal food drug cosmetic act federal state statutes regulations govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming fda must approve drug sold united states general process approval follows preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind application drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term table contents involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data phase clinical trials show adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california including san dimas facilities also must licensed state california compliance local regulatory requirements manufacturing facilities located canada including edmonton alberta facility facilities located near dublin cork ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious life threatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible accelerated priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited priority review viread truvada atripla received accelerated approval priority reviews drugs receiving accelerated approval must monitored postmarketing clinical trials order confirm safety benefits drug drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union includes major countries europe centralized approval procedure used approval table contents one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries pricing reimbursement successful commercialization products depends part availability governmental third party payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities third party payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices example significant portion sales majority products subject significant discounts list price rebate obligations addition increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product revenues profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited patients transitioning medicaid medicare part since longer term impact medicare part business clear impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category third party payers providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare pricing increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules president obamas administration united states congress made healthcare reform top priority proposed reforms extend coverage millions uninsured americans reduce rate growth costs governmentsponsored healthcare programs impending reform legislation congress may include reducing coverage reimbursement products additional healthcare reform costs borne pharmaceutical biotechnology companies including us could adverse impact business europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months table contents reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products expect continue countries attempt manage health care expenditures especially light global economic downturn new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth government agencies also issue regulations guidelines directly applicable us products addition time time professional societies practice management groups private healthscience foundations organizations publish guidelines recommendations directed certain health care patient communities recommendations guidelines may relate matters product usage dosage route administration use related competing therapies consequently result increased decreased usage products health care fraud abuse laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claims laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws prohibit anyone knowingly willingly presenting causing presented payment third party payers including medicare medicaid claims reimbursed drugs services false fraudulent claims items services provided claimed claims medically unnecessary items services sales marketing activities may subject scrutiny laws violations fraud abuse laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid government allege convict us violating laws could material adverse effect results operations august received subpoena office inspector general us department health human services requesting documents regarding development marketing sales ranexa cooperating continue cooperate related governmental inquiry compulsory licenses number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil table contents brazilian government purchased approximately million hiv products anticipate purchases hiv products brazilian government similar level addition concerns cost availability tamiflu related potential avian flu hn influenza pandemic generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit third party manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit third party manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement patents third party manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales employees january approximately fulltime employees believe good relations employees environment health safety seek comply applicable statutory administrative requirements concerning environmental quality worker health safety made continue make expenditures environmental compliance protection expenditures expected material effect capital expenditures results operations competitive position voluntarily assessing greenhouse gas emissions begun take action reduce emissions example establishing employee commuter programs evaluating energy efficiency buildings various laws regulations implemented consideration mitigate effects climate change caused greenhouse gas emissions example california air resources board process drafting regulations meet state emissions targets based current information subject finalization proposed regulations believe primary risk related climate change risk increased energy costs however energy intensive business anticipate subject cap trade system mitigation measures would likely material capital expenditures results operations competitive position also subject federal state local regulations regarding workplace safety protection environment use hazardous materials chemicals viruses various radioactive compounds rd activities eliminate risk accidental contamination injury materials certain misuse accidents involving materials could lead significant litigation fines penalties information subject information requirements exchange act therefore file periodic reports proxy statements information sec reports proxy statements information may obtained visiting public reference room sec f street ne washington dc calling sec sec sending electronic message sec publicinfosecgov sending fax sec addition sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically table contents mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section make available following filings soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act filings available free charge upon request item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales hiv products particularly truvada atripla unable maintain continue increasing sales products results operations may adversely affected currently dependent sales products treatment hiv infection particularly truvada atripla support existing operations hiv products contain tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv change causing nucleosidebased therapeutics fall favor unable continue increasing hiv product sales results operations would likely suffer would likely need scale back operations including spending research development rd efforts year ended december truvada atripla product sales together billion total revenues may able sustain growth rate sales hiv products especially truvada atripla number reasons including limited following hiv products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues hiv products mature private insurers government reimbursers often reduce amount reimburse patients products increases pressure us reduce prices large part market hiv products consists patients already taking hiv drugs successful encouraging physicians change patients regimens include hiv products sales hiv products limited generic hiv products introduced major markets ability maintain pricing market share may affected portion pretax income derived royalty revenue recognized sales tamiflu roche sales tamiflu decrease pretax income disproportionately adversely affected f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu worldwide treatment prevention influenza royaltypaying collaborative agreement us recognized million royalty revenue year ended december related royalties received sales table contents tamiflu roche although royalty revenue represented approximately total revenues represented pretax income period roches tamiflu sales unpredictable variability due strong relationship global pandemic planning efforts sales tamiflu increased sharply primarily result pandemic planning initiatives worldwide sales tamiflu decrease royalty revenues decrease pretax income decrease disproportionately decrease could material could adversely impact operating results inability accurately estimate demand products well sales fluctuations result inventory levels held wholesalers pharmacies non retail customers make difficult us accurately forecast sales may cause earnings fluctuate could adversely affect financial results stock price approximately product sales united states three wholesalers cardinal health inc mckesson corp amerisourcebergen corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesale locations inventory management agreements control buying patterns adverse changes economic conditions factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed example second quarter wholesalers increased inventory levels atripla truvada inventory levels viread decreased third quarter wholesalers drew inventory inventory levels atripla truvada end third quarter consistent levels held first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition nonretail sector united states includes government institutions including state aids drug assistance programs adap correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarter quarter fluctuations necessarily mirror purchasing patterns seen within retail sector example first quarter observed large nonretail purchases small number state adaps purchase centrally significant warehousing capacity believe purchases driven grant cycle federal adap funds rather current patient demand tempered orders associated product sales revenues earnings second quarter organizations depleted increased inventory levels established first quarter expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future estimate future demand products consider shelf life inventory regularly review realizability inventory actual demand less estimated demand could required record inventory writedowns would adverse impact results operations stock price fail commercialize new products expand indications existing products prospects future revenues may adversely affected introduce new products market increase sales existing products able increase maintain total revenues continue expand rd efforts example december announced phase clinical trial evaluating darusentan treatment resistant hypertension achieve coprimary efficacy endpoints result outcome decided discontinue development darusentan treatment resistant hypertension table contents approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid predict future fluctuations foreign currency exchange rate us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar face significant competition face significant competition large pharmaceutical biotechnology companies substantially greater resources addition competitors products operated fields compete longer hiv products compete primarily products joint venture established glaxosmithkline inc gsk pfizer inc pfizer markets fixeddose combination products compete truvada atripla may compound patent covering epivir lamivudine expire lamivudine marketed joint venture established gsk pfizer competitive emtricitabine active pharmaceutical ingredient emtriva component truvada atripla certain third party payors plans may use entry generic lamivudine reason exert pricing pressure hiv products hepsera viread treatment chronic hepatitis b compete primarily products produced gsk bristolmyers squibb company bms novartis pharmaceuticals corporation novartis united states european union china ambisome compete primarily products produced merck co inc merck pfizer addition aware least two lipid formulations claim similarity ambisome becoming available outside united states including possible entry one formulation greece formulations may reduce market demand ambisome furthermore manufacture lipid formulations amphotericin b complex formulations found unsafe sales ambisome may negatively impacted association letairis competes directly actelion pharmaceuticals us inc actelion indirectly pah products united therapeutics corporation pfizer ranexa competes predominantly generic compounds three distinct classes drugs betablockers calcium channel blockers longacting nitrates treatment chronic angina united states cayston competes product marketed novartis tamiflu competes products sold gsk generic competitors addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical table contents companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs significant safety issues arise marketed products product candidates future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products product letairis approved us food drug administration fda june member class compounds called endothelin receptor antagonists eras pose specific risks including serious risks liver injury birth defects risks letairis available letairis education access program leap restricted distribution program intended help physicians patients learn risks associated product assure appropriate use product product used additional patients may discover new risks associated letairis may result changes distribution program additional restrictions use letairis may decrease demand product example since launch letairis cases edema certain patients taking letairis reported information recently added product label may negatively impact demand product serious safety resistance drug interaction issues arise marketed products including letairis sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda comparable regulatory agencies countries continuing clinical trials truvada atripla viread hepsera emtriva ambisome letairis ranexa cayston currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis marketed products manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution september president bush signed law food drug administration amendments act significantly expanded fdas authority including among things require sponsors marketed products conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk table contents mandate labeling changes products point products lifecycle based new safety information require sponsors implement risk evaluation mitigation strategy product could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed sponsor fda could result significant civil monetary penalties operating results may adversely affected results anticipated timelines clinical trials uncertain may support continued development product pipeline would adversely affect prospects future revenue growth required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted example december announced phase clinical trial evaluating darusentan treatment resistant hypertension achieve coprimary efficacy endpoints result outcome decided discontinue development darusentan treatment resistant hypertension addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth would adversely impacted example face numerous risks uncertainties product candidates including elvitegravir novel hiv integrase inhibitor treatment hiv infection fixeddose regimen truvada tmc treatment hiv infection ambrisentan treatment idiopathic pulmonary fibrosis ipf currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn decrease revenues harm business due reliance third party contract research organizations conduct clinical trials unable directly control timing conduct expense quality clinical trials extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent third party contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed third party cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely impacted table contents results operations could adversely affected current potential future health care reforms legislative regulatory changes government prescription drug procurement reimbursement programs occur relatively frequently united states foreign jurisdictions significant changes federal medicare system recent years united states could impact pricing products medicare prescription drug improvement modernization act medicare beneficiaries able elect coverage prescription drugs medicare part prescription drug program began january although benefited patients transitioning medicaid medicare part since longer term impact medicare part business clear impact depend part specific decisions regarding level coverage provided therapeutic categories products included terms coverage provided extent preference given selected products category third party payers providing medicare part coverage attempted negotiate price concessions pharmaceutical manufacturers addition discussions taking place federal level pass legislation would either allow require federal government directly negotiate price concessions pharmaceutical manufacturers set minimum requirements medicare pricing increasing pressure lower prescription drug prices may limit drug access medicare part enrollees medicare patients pay coinsurance may influence products recommended physicians selected patients addition federal medicare proposals state medicaid drug payment changes could also lower payment products extent private insurers managed care programs follow medicaid coverage payment developments adverse effects may magnified private insurers adopting lower payment schedules president obamas administration united states congress made healthcare reform top priority proposed reforms extend coverage millions uninsured americans reduce rate growth costs governmentsponsored healthcare programs impending reform legislation congress may include reducing coverage reimbursement products additional healthcare reform costs borne pharmaceutical biotechnology companies including us could adverse impact business depend relationships companies sales marketing performance revenues failure maintain relationships poor performance companies disputes companies could negatively impact business rely number significant collaborative relationships major pharmaceutical companies sales marketing performance certain territories include collaborations bms atripla united states europe canada roche tamiflu gsk ambrisentan territories outside united states countries rely international distributors sales truvada viread hepsera emtriva ambisome relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors table contents corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us particularly light current economic conditions given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline april licensing agreement gsk gave gsk right control clinical regulatory development commercialization hepsera territories asia africa latin america include major markets hepsera china japan taiwan south korea november entered agreement gsk provided gsk exclusive commercialization rights registration responsibilities viread treatment chronic hbv china success hepsera viread treatment chronic hbv territories depends almost entirely efforts gsk regard gsk promotes epivirhbvzeffix product competes hepsera consequently gsks marketing strategy hepsera viread treatment chronic hbv may influenced promotion epivirhbvzeffix receive royalties gsk equal percentage gsks net sales hepsera viread treatment chronic hbv well net sales gsks epivirhbvzeffix gsk fails devote sufficient resources succeed developing commercializing hepsera viread treatment chronic hbv territories potential revenues territories may substantially reduced addition cayston letairis distributed third party specialty pharmacies pharmacies specializing dispensing medications complex chronic conditions may require high level patient education ongoing counseling use specialty pharmacies requires significant coordination sales marketing medical affairs regulatory affairs legal finance organizations involves risks including limited risks specialty pharmacies provide us accurate timely information regarding inventories patient data safety complaints effectively sell support cayston letairis devote resources necessary sell cayston letairis volumes within time frames expect able satisfy financial obligations us others cease operations also rely third party administer leap restricted distribution program designed support letairis third party provides information education prescribers patients risks letairis confirms insurance coverage investigates alternative sources reimbursement assistance ensures fulfillment risk management requirements mandated letairis fda coordinates controls dispensing patients third party specialty pharmacies failure third party specialty pharmacies distribute letairis perform expected may result regulatory action fda decreased letairis sales either would harm business cayston may taken patients using specific inhalation device delivers drug lungs patients commercial launch cayston ongoing distribution cayston entirely reliant upon manufacturer device example manufacturer could encounter issues regulatory agencies related device unable supply sufficient quantities device time commercial launch following commercial launch addition manufacturer may able provide table contents adequate warranty support device distributed patients respect distribution drug device patients reliant capabilities specialty pharmacies example distribution channel drug device complicated requires coordination reimbursement approval processes associated drug device similarly complex device manufacturer unable obtain reimbursement approval receives approval lowerthanexpected price sales cayston may adversely affected previously described issues may limit delay commercial launch cayston would adversely affect financial results existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental third party payer reimbursement cost products related treatments government health administration authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities third party payers increasingly attempting limit regulate price medical products services particularly new innovative products therapies resulted lower average selling prices example significant portion sales majority products subject significant discounts list price rebate obligations addition increased emphasis managed healthcare united states country regional pricing reimbursement controls european union put additional pressure product pricing reimbursement usage may adversely affect product revenues profitability pressures arise rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement policies pricing general europe success commercialized products product candidates may develop depend largely obtaining maintaining government reimbursement many european countries patients unlikely use prescription drugs reimbursed governments addition negotiating prices governmental authorities delay commercialization months reimbursement policies may adversely affect ability sell products profitable basis many international markets governments control prices prescription pharmaceuticals including implementation reference pricing price cuts rebates revenuerelated taxes profit control expect prices prescription pharmaceuticals decline life product volumes increase recently many countries european union increased amount discounts required products expect continue countries attempt manage health care expenditures especially light global economic downturn new drugs come market may face significant price decreases products across european countries believe continue foreseeable future governments struggle escalating health care spending result pricing practices may become difficult maintain historic levels profitability achieve expected rates growth expenses associated clinical trials may cause earnings fluctuate could adversely affect stock price clinical trials required regulatory approval products well clinical trials required conduct approval expensive difficult accurately predict control amount timing expenses quarter quarter fda andor regulatory agencies may require clinical testing originally anticipated uneven unexpected spending programs may cause operating results fluctuate quarter quarter stock price may decline table contents success depend significant degree ability protect patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents companies could require us stop using pay use required technology patents proprietary rights important business success depend significant degree ability obtain patents licenses patent rights preserve trade secrets operate without infringing proprietary rights others properly designed enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete patents addition competitors file patent applications covering technology may participate interference proceedings litigation determine right patent litigation interference proceedings expensive even ultimately successful results operations may adversely affected events time time certain individuals entities may challenge patents example public patent foundation filed requests reexamination united states patent trademark office pto challenging four patents related tenofovir disoproxil fumarate active ingredient truvada atripla viread pto granted requests issued nonfinal rejections four patents step common proceeding initiate reexamination process pto confirmed patentability four patents although successful responding pto office actions instance similar organizations may still challenge patents foreign jurisdictions example april brazilian health ministry citing us patent reexamination proceedings grounds rejection requested brazilian patent authority issue decision supportive patent application tenofovir disoproxil fumarate brazil august examiner brazilian patent authority issued final rejection fumarate salt patent application patent application tenofovir disoproxil fumarate filed brazil filed appeal within patent authority responding questions raised rejection july brazilian patent authority rejected application highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority predict outcome proceeding tenofovir disoproxil fumarate patent application unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil another example patent office india initially allowed claims covering tenofovir disoproxil tenofovir disoproxil fumarate however indian civil procedure prior official grant allowed applications several parties filed legal actions protest decision grant patents august indian patent office announced decided actions us would therefore allow patents granted filed table contents appeal within indian patent office applications predict outcome proceedings unable successfully appeal decisions appeals pursued indian court system may ultimately prove unsuccessful meantime competitor able sell generic tenofovir disoproxil fumarate india addition unable successfully appeal negative decisions indian patent office indian courts competitors would able continue sell generic tenofovir disoproxil fumarate could reduce amount royalties receive indian generic licenses brazilian government purchased approximately million hiv products anticipate purchases hiv products brazilian government similar level patents cover ranolazine active ingredient ranexa instead discovered sustained release formulation ranolazine would achieve therapeutic plasma levels patents obtained formulations characteristic plasma levels achieve patents cover active ingredients ambisome addition patent filings china certain asian countries covering forms adefovir dipivoxil active ingredient hepsera asia major market therapies hepatitis b indication hepsera developed may obtain patents certain products many years marketing approval obtained products patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions part approval process products fda granted exclusivity period manufacturers applications approval generic versions product granted generic manufacturers often wait challenge patents protecting products granted exclusivity one year prior end exclusivity period time time received notices manufacturers indicating intend import chemical intermediates possibly use making products therefore possible generic manufacturers considering attempts seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug patents subject challenges may need spend significant resources defend challenges may able defend patents successfully example november received notice teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir patents protecting viread january also received notices teva amending andas related truvada atripla notice related truvada teva challenged four patents related tenofovir two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir two additional patents related emtricitabine two patents related efavirenz expect file lawsuit teva infringement four viread patents two additional emtricitabine patents bms merck rights enforce defend patents related efavirenz predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection truvada atripla viread united states could substantially shortened patents covering products invalidated fda could approve tevas request manufacture generic version products table contents success depends large part ability operate without infringing upon patents proprietary rights third parties may filed another lawsuit teva infringement two emtricitabine patents infringe patents others may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware body patents may relate operation leap restricted distribution program designed support letairis addition actelion markets tracleer applied patent claims method use eras treatment ipf issued patent may interfere efforts commercialize era ambrisentan treatment ipf furthermore use significant proprietary technology rely unpatented trade secrets proprietary knowhow protect certain aspects production technologies trade secrets may become known independently discovered competitors manufacturing problems could delay product shipments regulatory approvals may adversely affect results operations depend third parties perform manufacturing activities effectively timely basis majority solid dose products addition roche either third parties responsible manufacturing tamiflu manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations third party manufacturers corporate partners subject fdas current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards similar regulations effect countries manufacturing operations also subject routine inspections regulatory agencies additionally third party manufacturers corporate partners independent entities subject unique operational financial risks control third party manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties cause delays clinical trials applications regulatory approval extent risks materialize affect performance obligations us financial results may adversely affected ability successfully manufacture commercialize cayston depend upon ability manufacture multiproduct facility aztreonam active pharmaceutical ingredient cayston monobactam gramnegative antibiotic manufacture third parties multiproduct manufacturing facilities historically fda permitted manufacture monobactams multiproduct manufacturing facilities however assurance fda continue allow practice currently singleproduct facility dedicated manufacture cayston engaged contract manufacturer singleproduct facility cayston fda prohibits manufacture mono bactam antibiotics like aztreonam multiproduct manufacturing facilities future may able procure singleproduct manufacturing facility timely manner would adversely affect commercial supplies cayston anticipated financial results attributable product may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products light economic downturn increased difficulty purchasing certain raw materials used table contents manufacturing process unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named nda filed fda product candidate seeking fda approval significant delays occur qualification new supplier required even manufacturer qualified fda manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections fda following initial approval result inspections fda determines equipment facilities laboratories processes comply applicable fda regulations conditions product approval fda may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility example manufacture ambisome cayston fill finish macugen exclusively facilities san dimas california event disaster including earthquake equipment failure difficulty may unable replace manufacturing capacity timely manner may unable manufacture ambisome cayston macugen meet market needs cayston dependent three different third party singlesource suppliers first aztreonam active pharmaceutical ingredient aztreonam inhalation solution manufactured single supplier single site second administered lungs patients device made single supplier single site third diluent cayston manufactured single manufacturer single site disruptions delays single suppliers could adversely affect ability produce cayston adequate quantities support commercial launch cayston sure alternative suppliers identified timely manner addition depend single supplier high quality cholesterol used manufacture ambisome also depend single suppliers active pharmaceutical ingredient vistide ranexa cayston tableting emtiva letairis astellas us llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problems single suppliers depend may negatively impact development commercialization efforts face credit risks european customers may adversely affect results operations european product sales governmentowned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices resulted may continue result increase days sales outstanding due average length time accounts receivable outstanding accounts receivable countries totaled approximately million december million days past due based contractual payment terms historically receivables balances certain government owned hospitals accumulated period time subsequently settled large lump sum payments significant changes occur reimbursement practices european governments government funding becomes unavailable may able collect amounts due us customers results operations would adversely affected example december million due publiclyowned hospitals greece event greek government defaulted debt may unable collect amounts due table contents product revenues gross margin could reduced imports countries products available lower prices prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets cases pharmaceutical products sold steeply discounted prices developing world reexported european countries could resold much higher prices happens products particularly truvada viread agreed make available substantially reduced prices countries participating gilead access program atripla merck distributes substantially reduced prices hiv infected patients developing countries august agreement revenues would adversely affected addition established partnerships thirteen indian generic manufacturers distribute highquality lowcost generic versions tenofovir disoproxil fumarate developing world countries including india generic versions medications licenses reexported united states europe markets outside countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter example european union required permit products purchased one country sold another country purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business countries may required grant compulsory licenses products face generic competition products number developing countries government officials interested groups suggested pharmaceutical companies make drugs hiv infection available low cost alternatively governments developing countries could require grant compulsory licenses allow competitors manufacture sell versions products thereby reducing product sales example past certain offices government brazil expressed concern affordability hiv products declared considering issuing compulsory licenses permit manufacture otherwise patented products hiv infection including viread july brazilian patent authority rejected patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread highest level appeal available us within brazilian patent authority filed civil action brazilian federal court appeal action brazilian patent authority unable successfully appeal decision patent authority courts brazilian government would likely purchase generic tenofovir disoproxil fumarate would significantly reduce sales hiv products brazil brazilian government purchased approximately million hiv products anticipate purchases hiv products brazilian government similar level addition concerns cost availability tamiflu related potential avian flu pandemic hn influenza generated international discussions compulsory licensing tamiflu patents example canadian government may allow canadian manufacturers manufacture export active ingredient tamiflu eligible developing least developed countries canadas access medicines regime furthermore roche issued voluntary licenses permit third party manufacturing tamiflu example roche granted sublicense shanghai pharmaceutical group co ltd china sublicense indias hetero drugs limited india certain developing countries one compulsory licenses issued permitting generic manufacturing override tamiflu patents roche issue additional voluntary licenses permit third party manufacturing tamiflu developments could reduce royalties receive roches sales tamiflu certain countries permit enforcement table contents patents third party manufacturers able sell generic versions products countries compulsory licenses sales generic versions products could significantly reduce sales adversely affect results operations particularly generic versions products imported territories existing commercial sales may face significant liability resulting products may covered insurance successful claims could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others recent years coverage availability costeffective product liability insurance decreased addition cost defend lawsuits pay damages product liability claims may exceed coverage unable maintain adequate coverage claims exceed coverage financial condition ability clinically test product candidates market products adversely impacted addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition assumptions used determine selfinsurance levels could wrong materially impact business continually evaluate levels selfinsurance based historical claims experience demographic factors severity factors actuarial assumptions however future occurrences claims differ assumptions historical trends business financial results financial condition could materially impacted claims expenses expensive litigation government investigations may reduce earnings november received notice teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir patents protecting viread january also received notices teva amending andas related truvada atripla notice related truvada teva challenged four patents related tenofovir two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir two additional patents related emtricitabine two patents related efavirenz expect file lawsuit teva infringement four viread patents two additional emtricitabine patents bms merck rights enforce defend patents related efavirenz predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection truvada atripla viread united states could substantially shortened patents covering products invalidated fda could approve tevas request manufacture generic version products addition along certain officers former officer named defendants class action lawsuit alleging violations federal securities laws august received subpoena office inspector general us department health human services requesting documents regarding development marketing sales ranexa cooperating continue cooperate related governmental inquiry table contents outcome lawsuits lawsuits may brought us investigation investigations brought us inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business changes effective income tax rate could reduce earnings various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact net income income tax returns audited federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period changes accounting rules policies may affect financial position results operations us generally accepted accounting principles related implementation guidelines interpretations highly complex involve subjective judgments changes rules interpretation adoption new guidance application existing guidance changes business could significantly affect financial position results operations fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms unsuccessful recruitment retention efforts business may harmed item b unresolved staff comments applicable item properties corporate headquarters including principal offices commercial administrative research development rd facilities located foster city california buildings lease facilities foster city palo alto san dimas california house manufacturing warehousing rd activities addition also lease facilities durham north carolina boulder westminster colorado seattle washington house administrative rd activities international headquarters include commercial medical administrative facilities located leased london area united kingdom utilize manufacturing facility cork ireland primarily solid dose tablet manufacturing antiviral products well product packaging activities also lease facilities dublin area ireland house distribution activities table contents also manufacturing facility edmonton alberta canada primarily use conduct process research scaleup clinical development candidates manufacturing active pharmaceutical ingredients investigational commercial products chemical development activities improve existing commercial manufacturing processes leased additional facilities house commercial medical administrative activities australia austria belgium canada france germany greece ireland italy netherlands portugal spain sweden switzerland turkey united kingdom believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings november received notice teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version truvada notice teva alleges two patents associated emtricitabine owned emory university licensed exclusively us invalid unenforceable andor infringed tevas manufacture use sale generic version truvada december filed lawsuit us district court new york teva infringement two emtricitabine patents march received notice teva submitted anda fda requesting permission manufacture market generic version atripla notice teva challenged two emtricitabine patents may filed another lawsuit us district court new york teva infringement two emtricitabine patents lawsuit consolidated lawsuit filed december january received notice teva submitted anda fda requesting permission manufacture market generic version viread notice teva challenged four tenofovir patents protecting viread january also received notices teva amending andas related truvada atripla notice related truvada teva challenged four patents related tenofovir two additional patents related emtricitabine notice related atripla teva challenged four patents related tenofovir two additional patents related emtricitabine two patents related efavirenz expect file lawsuit teva infringement four viread patents two additional emtricitabine patents bms merck rights enforce defend patents related efavirenz predict ultimate outcome actions may spend significant resources enforcing patents unsuccessful lawsuits original claims patents may narrowed invalidated patent protection truvada atripla viread united states could substantially shortened patents covering products invalidated fda could approve tevas request manufacture generic version products information pertaining certain legal proceedings found heading legal proceedings item note consolidated financial statements included annual report incorporated reference herein item reserved table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild following table sets forth high low intraday sale prices per share common stock nasdaq global select market periods indicated prices represent quotations among dealers without adjustments retail markups markdowns commissions may represent prices actual transactions high low first quarter second quarter third quarter fourth quarter first quarter second quarter third quarter fourth quarter february shares common stock outstanding held approximately stockholders record paid cash dividends common stock since inception currently expect retain earnings primarily use operation expansion business therefore anticipate paying cash dividends near future effort return value stockholders minimize dilution stock issuances board directors board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means december completed share repurchases program january board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires january see item note consolidated financial statements included annual report information regarding stock repurchase program table contents performance graph following graph compares total stockholder returns past five years two indices standard poors stock index labeled sp index nasdaq biotechnology index labeled nbi index total return index assumes reinvestment dividends paid companies included indices calculated december year composite member sp index nbi index intend use indices comparators stock performance purposes following graph going forward composite member sp index required applicable regulations use index comparator believe nbi index relevant comparator since composed peer companies linesofbusiness similar stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december table contents issuer purchases equity securities october board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated share repurchase transactions similar arrangements december completed share repurchases program january board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires january table summarizes stock repurchase activity three months ended december thousands except per share amounts maximum total number fair value shares total number shares purchased may yet shares average price part publicly purchased purchased paid per share announced programs program october october november november december december total difference total number shares purchased total number shares purchased part publicly announced programs due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations table contents item selected financial data gilead sciences inc selected consolidated financial data thousands except per share data year ended december consolidated statement operations data total revenues purchased inprocess research development total costs expenses income loss operations provision income taxes net income loss attributable gilead net income loss per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income loss per share attributable gilead common stockholders diluted shares used per share calculationdiluted december consolidated balance sheet data cash cash equivalents marketable securities working capital total assets longterm obligations convertible senior notes retained earnings accumulated deficit total stockholders equity completed acquisition assets navitas assets llc related cicletanine business aggregate purchase price million allocated purchased inprocess research development iprd completed acquisition myogen inc aggregate purchase price billion billion allocated purchased iprd million allocated deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated goodwill million allocated net tangible assets also acquired net assets corus pharma inc million million allocated purchased iprd million allocated net table contents gilead sciences inc selected consolidated financial datacontinued deferred tax assets primarily related federal net operating loss tax credit carryforwards certain state amortizations million allocated net tangible assets million allocated assembled workforce recognized million royalty revenue relating resolution dispute f hoffmannla roche ltd together hoffmannla roche inc also recorded tax provision benefit million related repatriation qualified foreign earnings american jobs creation act ajca adopted guidance measuring recognizing sharebased payments employees directors including grants stock options beginning january see notes consolidated financial statements annual report january adopted guidance convertible senior notes retrospective basis guidance required us bifurcate conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt see item note consolidated financial statements included annual report form k january adopted guidance joint ventures bms retrospective basis result adopting guidance presented noncontrolling interest consolidated statements income net loss attributable noncontrolling interest component consolidated net income retrospective basis see item note consolidated financial statements included annual report completed acquisition cv therapeutics inc recognized consideration transferred billion primarily recorded intangible assets see item note consolidated financial statements included annual report issued billion principal amount convertible senior notes private placement entered uncollateralized million term loan agreement facilitate cash dividend distribution part repatriation qualified foreign earnings provisions ajca table contents item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia market products hivaids liver diseases respiratory cardiovascularmetabolic therapeutic areas products comprise truvada emtricitabine tenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus hiv infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infections letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptoms cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu oseltamivir phosphate treatment prevention influenza royaltypaying collaborative agreement us eyetech inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelated macular degeneration royaltypaying collaborative agreement us glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaying collaborative agreement us menarini international operations luxembourg sa markets ranexa outside united states royaltypaying collaborative agreement us astellas us llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi royaltypaying collaborative agreement us business highlights grew business significantly achieved record total revenues billion strengthening product portfolio pipeline programs commercial achievements comprised continued rollout atripla european union including launch atripla france growth atripla truvada product sales united states canada making gains pah market letairis well continuing expansion sales marketing infrastructure grew product sales significantly continued strengthen worldwide organization infrastructure support expanded international footprint business activities addition added ranexa product portfolio acquisition cv therapeutics inc cv therapeutics april february received marketing approval us food drug administration fda cayston treatment improve respiratory symptoms cf patients p aeruginosa cayston conditionally approved europe canada september cayston delivered via specific inhalation device developed pari pharma gmbh table contents also made significant advances compounds product candidates research development rd pipeline including hiv area january announced phase clinical studies cobicistat formerly gs pharmacoenhancer development boosting agent certain hiv medicines complete singletablet fixeddose regimen containing elvitegravir cobicistat truvada treatmentnave patients met primary objectives noninferiority pending discussion fda expect initiate three phase studies middle two studies singletablet fixeddose regimen mentioned one study cobicistat december completed enrollment phase study evaluating elvitegravir treatmentexperienced patients addition collaboration tibotec pharmaceuticals tibotec developing new oncedaily fixeddose combination containing truvada tibotecs investigational non nucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trials subject positive outcome study intend submit marketing applications fixeddose combination truvada tmc united states europe second half liver disease area completed phase studies gs caspase inhibitor licensed lg life sciences ltd development treatment hepatitis c nonalcoholic steatohepatitis expect present results second quarter continuing phase b study gs treatment hepatitis c also continuing phase study gs nonnucleoside polymerase inhibitor evaluated treatment hepatitis c infection expect complete study second half cardiovascular metabolic areas expanded product candidate portfolio acquisition cv therapeutics anticipate commencing patient enrollment phase study ranolazine treatment diastolic heart failure patients preserved ejection fraction second quarter continuing phase study ambrisentan patients pulmonary hypertension secondary idiopathic pulmonary fibrosis ipf also collaborating gsk develop clinical trial study combination therapy versus monotherapy firstline treatment setting pah study ambition evaluate firstline combination use ambrisentan endothelin receptor antagonist era tadalafil pde inhibitor patients pah continuing phase study cicletanine hydrochloride oral agent development treatment pah announced plans terminate development darusentan treatment resistant hypertension second phase study compound failed meet coprimary efficacy endpoints may announced marketing authorization application regadenoson investigational pharmacologic stress agent radionuclide mpi validated european medicines agency emea following validation marketing authorization application dossier distributed members committee medicinal products human use chmp formal review determine whether regadenoson safe efficacious pharmacologic stress agent humans respiratory area continuing phase study ambrisentan treatment ipf anticipate completing enrollment patients study end continuing phase study gs inhaled coformulation fosfomycin tobramycin treatment bacterial infections associated cf phase study aztreonam inhalation solution treatment bronchiectasis phase study gs oral epithelial sodium channel blocker designed increase airway hydration treatment pulmonary disease acquisition cv therapeutics restructuring april completed acquisition cv therapeutics publiclyheld biopharmaceutical company based palo alto california primarily focused discovery development commercialization small molecule drugs treatment cardiovascular metabolic pulmonary diseases cv therapeutics table contents two marketed products well several product candidates clinical development treatment cardiovascular metabolic pulmonary diseases believe acquisition provide us opportunity expand cardiovascular therapeutic area adopted new business combinations guidance recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree applied cv therapeutics acquisition result recognized consideration transferred billion recorded million million intangible assets relating marketed products inprocess research development iprd projects respectively constituted significant portion assets acquired cv therapeutics results operations cv therapeutics beginning april acquisition date included consolidated financial statements year ended december second quarter approved plan realize certain synergies cv therapeutics us realign cardiovascular operations eliminate certain redundancies restructuring plan included consolidation realignment cardiovascular rd organization exit certain facilities termination certain contractual obligations result restructuring plan recorded million million selling general administrative sga expenses rd expenses respectively primarily related employee severance relocation termination benefits lease termination costs facilitiesrelated expenses expect incur additional million bringing total amount incurred connection significant activities restructuring plan approximately million employee severance relocation termination benefits million facilitiesrelated expenses financial highlights operating results year led total product sales billion antiviral product sales truvada atripla viread hepsera emtriva increased billion billion key drivers total product sales growth compared continued uptake atripla united states europe atripla contributed billion total antiviral product sales growth atripla product sales increased proportion overall product sales caused total product gross margin decrease due primarily efavirenz component atripla sales zero gross margin truvada product sales comprised billion total antiviral product sales truvada product sales increased primarily due continued sales volume growth united states europe foreign currency fluctuations unfavorable impact approximately million total revenues million pretax income compared royalty revenues recognized collaborations corporate partners million increase royalty revenues million increase royalty revenues due primarily increased tamiflu sales roche related pandemic planning initiatives worldwide operating expenses increased million compared reflecting increased research clinical study activity development pipeline expanded commercial activities worldwide well higher headcount infrastructure technologyrelated costs required support continued growth business cash cash equivalents marketable securities increased million year driven primarily operating cash flows billion partially offset cash used acquire cv therapeutics billion net cash cash equivalents marketable securities acquired cv therapeutics million million used repurchase approximately million shares common stock open market purchases completed billion stock repurchase program authorized board directors board october table contents outlook operating objectives include increasing market share commercial products continuing strengthen pipeline internally developed andor externally inlicensed purchased opportunities strengthening key alliances commercial standpoint number internal external initiatives intended promote continued growth franchises hiv area expect favorable impact updated atripla label includes data study supporting switching patients hiv regimens atripla revised us department health human services treatment guidelines recommend earlier treatment patients hiv extension ryan white treatment act provide stable funding aids drug assistance programs united states hepatitis b virus hbv area continue support educational promotional activities focused asian communities highlighting need screen diagnose link patients care part efforts larger hepatitis b field team united states cardiovascular area continue efforts raise awareness gilead pah cardiology communities believe help grow revenues letairis ranexa mindful conditions current macroeconomic environment could affect ability achieve goals factors could affect business include potential healthcare reform united states continued government pricing pressures internationally potential volatility foreign currency exchange rates continue monitor factors adjust business processes mitigate risks business successes experienced helped us maintain build financially sound business model believe allow us continue expand commercial collaborative rd activities maintain quality compliance continue grow business achieve greater operational leverage remain focused profitable revenue growth prudent expense management believe enable solid execution operating objectives critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate estimates including related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition product sales recognize revenues product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured record estimated reductions revenues government rebates medicaid reimbursements customer table contents incentives cash discounts prompt payment distributor fees expected returns expired products estimates deducted gross product sales time revenues recognized reductions gross product sales government rebates significantly impact reported net product sales based upon certain estimates require complex significant judgment management government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs reimbursement portions retail price prescriptions filled covered programs reductions settled either company invoiced directly chargebacks wholesalers government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable although may pay rebates countries outside united states date payments made foreign governments represented significant portion total government rebates government programs united states estimate sales allowances based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs channel inventory data obtained major us wholesalers accordance inventory management agreements us government rebates million million million respectively representing total gross product sales respectively deducted gross product sales believe methodology use estimate sales allowances government price reductions reasonable appropriate given current facts circumstances however actual results may differ based current information available us actual government rebates claimed periods varied less estimates recorded periods december accrued us government rebates million million respectively accrued liabilities allowance million million respectively recorded accounts receivable following table summarizes aggregate activity us government rebates allowance accrued liabilities accounts balance deducted balance beginning charged end year expense accruals year year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total year ended december government rebates allowances accrued liabilities activity related sales activity related sales prior total intangible assets conjunction business combinations completed recorded intangible assets primarily related marketed products iprd projects goodwill part recognition measurement assets acquired liabilities assumed business combination identifiable intangible assets table contents related marketed products iprd projects measured respective fair values acquisition date believe fair values assigned acquired intangible assets based reasonable estimates assumptions given available facts circumstances acquisition dates discounted cash flow models used valuing intangible assets models require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets goodwill represents excess consideration transferred estimated fair values assets acquired liabilities assumed business combination goodwill intangible assets determined indefinite useful lives amortized required tested impairment least annually test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair values assets carrying amounts december million indefinitelived intangible assets consisting million goodwill resulting various business combinations million intangible assets related iprd projects acquired cv therapeutics million iprd intangible assets acquired cv therapeutics million related gs formerly cvt product candidate phase clinical studies treatment hypertriglyceridemia remaining balance intangible assets related iprd projects represented various inprocess projects single project comprising significant portion total value estimated fair value iprd intangible assets acquired cv therapeutics determined using income approach discounts expected future cash flows present value estimated fair value intangible assets using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar cv therapeutics comparable estimated internal rate return cv therapeutics operations represents rate market participants would use value intangible assets compensated differing phases development project probabilityadjusting estimation expected future cash flows associated project determined present value expected future cash flows using discount rate projected cash flows iprd projects based various estimates assumptions including noted intangible assets finite useful lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortizing intangible asset related ranexa product acquired cv therapeutics estimated useful life using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortizing intangible asset related lexiscan product also acquired cv therapeutics estimated useful life cost goods sold table contents straightline basis given current lexiscan revenues consist royalties received collaboration partner limited ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate utilizing forecasted product sales approach december million net unamortized finitelived intangible assets consisting primarily intangible assets related marketed products acquired cv therapeutics judgment regarding existence impairment indicators based historical projected future operating results extent manner use acquired assets legal regulatory factors events overall business strategy market economic trends events occur future cause us conclude impairment indicators exist certain intangible assets impaired financial condition results operations may adversely impacted allowance doubtful accounts also maintain allowance doubtful accounts estimated losses resulting inability customers make required payments allowance based analysis several factors including limited contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices financial condition customers economic environment operate deteriorate resulting inability make payments additional allowances may required allowance doubtful accounts balance percentage total accounts receivable materially change december december believe allowance doubtful accounts adequate cover anticipated losses current conditions however significant deterioration factors especially respect government funding reimbursement practices european market could materially change expectations may result increase allowance doubtful accounts prepaid royalties capitalize royalties prepaid cost specifically related emtricitabine royalties paid emory university emory hiv indication based present value future royalty obligation would expect pay emory assuming certain expected future levels product sales incorporating emtricitabine present value future royalty obligation derived using weightedaverage cost capital review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty potential indicators impairment include launch significant product competitor significant deviations recognized product sales compared forecast product safety issues recalls amortize prepaid royalties based effective royalty rate derive forecasted future hiv product sales incorporating emtricitabine product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts including introduction competing product us one competitors hiv market emtricitabine prospectively update royalty rate used amortize prepaid royalties may increase future cost goods sold record amortization expense december prepaid royalty asset relating emtricitabine royalties paid emory million million respectively amortization expense relating prepaid royalty asset million million million years ended december respectively table contents clinical trial accruals record accruals estimated clinical study costs clinical studies performed third party contract research organizations cros costs significant component rd expenses incurred cro costs million million million respectively accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros validate accruals quarterly vendors perform detailed reviews activities related significant contracts based upon results validation processes assess appropriateness accruals make adjustments deem necessary ensure expenses reflect actual effort incurred cros generally significant portion total clinical trial costs associated start activities trial patient enrollment extensively outsource clinical trial activities usually perform small portion startup activities inhouse result cros typically perform total startup activities trials including document preparation site identification screening preparation prestudy visits training program management startup costs usually occur within months contract executed milestone event driven nature remaining clinical activities related costs patient monitoring administration generally occur ratably throughout life individual contract study contracts negotiated fixed per unit prices vary length three months single dose phase clinical study two years complex phase clinical study average length contracts upper end range order provide longterm safety efficacy data support commercial launches truvada atripla viread hepsera emtriva letairis ranexa material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance relating uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated december differences actual estimated activity levels particular study material however management receive complete accurate information vendors underestimates activity levels associated study given point time may record additional potentially significant rd expenses future periods tax provision estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made adjustment made determined likely certain deferred tax assets would realized therefore released related valuation allowance resulted credit goodwill approximately million income tax benefit approximately million million respectively future effective income tax rate may affected factors changes tax laws regulations rates changing interpretation existing laws regulations impact accounting stockbased compensation changes international organization changes overall levels income tax table contents december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition reached agreement internal revenue service irs several issues related examinations federal income tax returns also amended california income tax returns based resolution certain tax positions irs result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onward certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years california income tax purposes statute limitations remains open years income tax returns audited federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period stockbased compensation measure sharebased payments employees directors including grants stock options based relative fair values fair values awards granted stock option plans employee stock purchase plan estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach nonvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual table contents forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation additional paidin capital apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic years ended december recognized stockbased compensation expenses million million million respectively operating expenses capitalized million million million respectively inventory december unrecognized stockbased compensation expenses million related nonvested stock options expect expense estimated weighted average period years management discussed development selection disclosure critical accounting policies audit committee board audit committee reviewed disclosure presented relating critical accounting policies results operations total revenues total revenues billion billion billion included total revenues product sales royalty revenues contract revenues product sales following table summarizes period period changes product sales thousands change change antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis ranexa total product sales total product sales increased compared compared due primarily overall increase antiviral product sales including strong growth atripla sales well continued growth truvada sales foreign currency denominated product sales experienced net loss appreciation us dollar approximately million compared net benefit depreciation us dollar approximately million compared significant percentage product sales continued denominated foreign currencies used foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro reduced eliminate fluctuations sales due changes foreign currency exchange rates table contents antiviral products antiviral product sales increased compared compared driven primarily sales volume growth atripla truvada increase compared also due favorable foreign currency exchange impact truvada truvada sales increased compared driven primarily sales volume growth united states europe partially offset unfavorable foreign currency exchange impact truvada sales increased compared driven primarily sales volume growth united states europe favorable foreign currency exchange impact truvada sales accounted total antiviral product sales respectively atripla atripla sales increased compared driven primarily sales volume growth united states europe european growth benefited launch atripla france second quarter atripla sales increased compared driven primarily continued uptake atripla united states well launches product european countries atripla sales include efavirenz portion zero product gross margin efavirenz portion atripla sales approximately million million million respectively atripla sales accounted total antiviral product sales respectively antiviral products antiviral product sales include product sales viread hepsera emtriva decreased compared driven primarily sales volume decreases hepsera partially offset sales volume increases viread treatment patients chronic hepatitis b antiviral product sales increased compared driven primarily increase hepsera sales benefited favorable foreign currency exchange impact well sales volume growth certain european countries ambisome sales ambisome increased compared driven primarily sales volume growth certain european markets partially offset unfavorable foreign currency exchange impact sales ambisome increased compared driven primarily favorable foreign currency exchange impact sales volume growth certain european markets ambisome product sales united states canada relate solely sales ambisome astellas pharma us inc recorded manufacturing cost letairis sales letairis treatment pah increased compared driven primarily sales volume growth united states sales letairis increased compared driven primarily sales volume growth united states letairis launched june ranexa sales ranexa million period april date acquisition cv therapeutics december expect total product sales continue grow continue expand sales marketing efforts table contents royalty revenues following table summarizes period period changes royalty revenues thousands change change royalty revenues significant source royalty revenues sales tamiflu roche royalty revenues million increase compared driven primarily recognition tamiflu royalties roche million compared tamiflu royalties roche million higher tamiflu royalties due increased tamiflu sales roche related primarily pandemic planning initiatives worldwide royalty revenues million decrease compared driven primarily recognition tamiflu royalties roche million compared tamiflu royalties roche million lower tamiflu royalties due primarily decreased roche sales related pandemic planning initiatives worldwide recognize royalties tamiflu sales roche quarter following quarter tamiflu sold cost goods sold product gross margin following table summarizes period period changes product sales thousands cost goods sold thousands product gross margin change change total product sales cost goods sold product gross margin product gross margin compared lower product gross margin due primarily higher proportion atripla sales include efavirenz portion zero product gross margin well amortization associated intangible assets acquired acquisition cv therapeutics product gross margin compared decrease product gross margin due primarily higher proportion atripla sales include efavirenz portion zero product gross margin impact changes product geographic mix product sales higher mix atripla product sales decreases overall product gross margin although record atripla product sales benefit product gross margin truvada portion atripla sales efavirenz portion atripla sales carries zero product gross profit gross margin since purchase efavirenz bristolmyers squibb company bms bmss net selling price efavirenz expect product gross margin lower compared due primarily higher proportion expected atripla sales table contents research development expenses following table summarizes period period changes major components rd expenses thousands change change research clinical development pharmaceutical development total research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed cros materials supplies licenses fees overhead allocations consisting various support facilitiesrelated costs rd activities separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs clinical trials pharmaceutical development expenses consist costs product formulation chemical analysis rd expenses increased million compared due primarily increased compensation benefits expenses million driven higher headcount related growth business rd expense reimbursement related tibotec tmc collaboration million increased clinical study expenses million increase compensation benefits expenses also driven severance termination benefits associated restructuring activities related acquisition cv therapeutics rd expenses increased million compared due primarily increased clinical study expenses million primarily antiviral cardiovascular areas well increased compensation benefits expenses million due primarily higher headcount general significant collaboration payments like made tibotec cause rd expenses fluctuate period period expect rd expenses increase levels due increased spending internal collaborative rd efforts anticipate product candidates progress advanced clinical studies well adding clinical development programs pipeline selling general administrative expenses following table summarizes period period changes sga expenses last three years thousands change change selling general administrative sga expenses increased million compared due primarily increased compensation benefits expenses million driven higher headcount related growth business increased contract professional services expenses million driven primarily expanding sales marketing activities million related certain contract termination costs increase compensation benefits expenses also driven severance termination benefits associated restructuring activities related acquisition cv therapeutics sga expenses increased million compared due primarily increased compensation benefits expenses million due largely higher headcount increased marketing table contents promotional expenses million support expanded commercial operations increased consulting support services expenses million related growth business costs million associated certain employee terminationrelated disputes international operations expect sga expenses increase levels due increased investment support growth hiv franchise full year impact sales marketing activities ranexa commercialization cayston believe appropriate infrastructure support growth business purchased inprocess research development expenses connection acquisition cicletanine assets navitas assets llc recorded iprd expense million year ended december consider acquisition material purchase made disclosures regarding related purchased iprd connection acquisition myogen recorded purchased iprd expenses billion year ended december related ambrisentan darusentan iprd projects acquired purchased iprd expense represented estimated fair value myogens incomplete rd projects yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition respect ambrisentan june fda approved letairis treatment pah united states additionally april european commission granted collaboration partner gsk marketing authorization ambrisentan treatment pah marketed name volibris gsk respect darusentan december announced plans terminate development darusentan treatment resistant hypertension second phase study compound failed meet coprimary efficacy endpoints connection acquisition corus pharma inc corus recorded purchased iprd expenses million year ended december related aztreonam inhalation solution cf iprd project acquired purchased iprd expense represented estimated fair value coruss incomplete rd project yet reached technological feasibility alternative future use acquisition date therefore expensed upon acquisition february received marketing approval fda cayston treatment improve respiratory symptoms cf patients p aeruginosa cayston conditionally approved europe canada september interest income net recorded interest income net million million million respectively decrease compared due primarily decreased interest income million driven reduction average yield investment portfolio result lower interest rates partially offset increase net foreign currency exchange gains million decrease compared due primarily increased costs related hedging activities million net foreign currency exchange losses million decreased interest income million due primarily lower interest rates partially offset writedowns certain securities recorded interest expense january adopted guidance convertible senior notes due notes convertible senior notes due notes collectively notes retrospective basis guidance requires us bifurcate conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt result retrospective adoption guidance reflected additional interest expense table contents million million respectively related benefit income taxes million million respectively recorded additional interest expense million related benefit income taxes million interest expense million million million respectively increases compared compared due primarily effect accreting debt discount notes additional interest expense expected life debt discussed provision income taxes provision income taxes million million million respectively effective tax rate differed us federal statutory rate due primarily tax credits resolution certain tax positions tax authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes revaluation certain state tax assets related integration cv therapeutics provide us income taxes undistributed earnings foreign operations intended permanently reinvested effective tax rate differs us federal statutory rate due primarily tax credits resolution certain tax positions tax authorities certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes effective tax rate differs us federal statutory rate due primarily tax credits certain operating earnings nonus subsidiaries considered indefinitely invested outside united states partially offset state taxes december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income reached agreement irs several issues related examinations federal income tax returns also amended california income tax returns based resolution certain tax positions irs result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities table contents liquidity capital resources following table summarizes cash cash equivalents marketable securities working capital cash flow activities end last three years thousands december cash cash equivalents marketable securities working capital year ended december cash provided used operating activities investing activities financing activities cash cash equivalents marketable securities cash cash equivalents marketable securities totaled billion december increase million december increase primarily attributable net cash provided operations billion proceeds issuances common stock employee stock plans million partially offset following cash used acquire cv therapeutics billion net cash cash equivalents marketable securities acquired cv therapeutics million million used repurchase common stock stock repurchase program million used extinguish convertible senior notes assumed acquisition cv therapeutics cash cash equivalents marketable securities totaled billion december increase million december increase primarily attributable net cash provided operations billion proceeds issuances common stock employee stock plans million increase partially offset repurchases billion common stock stock repurchase program working capital working capital billion december decrease million working capital december decrease primarily attributable increase million accounts payable due primarily purchases efavirenz estimated market value bms decrease million cash cash equivalents shortterm marketable securities since held higher proportion longterm marketable securities december compared december decrease partially offset increase million accounts receivable net driven primarily increased product sales table contents working capital december billion increase million december increase primarily attributable increase million inventories due primarily purchases efavirenz estimated market value bms increase million accounts receivable net driven primarily increased product sales increase million cash cash equivalents shortterm marketable securities increase partially offset million increase accounts payable due primarily purchases efavirenz estimated market value bms cash provided operating activities cash provided operating activities billion primarily related net income billion adjusted noncash items million stockbased compensation expenses million amortization expenses result adoption guidance joint ventures bms january reclassified change noncontrolling interest cash provided operating activities cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million tax benefits employee stock plans million stockbased compensation expenses partially offset million excess tax benefits stock option exercises reclassified cash used financing activities cash provided operating activities billion primarily related net income billion adjusted noncash items million stockbased compensation expenses million deferred income taxes million tax benefits related employee stock plans partially offset million net cash outflow related changes operating assets liabilities cash used investing activities cash used investing activities billion driven cash used acquisition cv therapeutics billion net cash acquired net use million purchases marketable securities million capital expenditures year capital expenditures made related primarily expansion manufacturing capabilities upgrades facilities spending computer laboratory equipment well enterprise software accommodate continued business growth capital expenditures also included purchase office building approximately acres land located foster city california cash used investing activities million driven primarily net use million purchases marketable securities million capital expenditures year cash used investing activities billion driven primarily net use billion purchases marketable securities cash used acquisition nycomed limited million net cash acquired million capital expenditures year capital expenditures included construction new building foster city california headquarters december capital expenditure commitments million consisted primarily enterprise software purchase commitments expect fulfill commitments funds generated operating cash flows table contents cash used financing activities cash used financing activities billion driven primarily million used repurchase common stock stock repurchase program million used extinguish convertible senior notes assumed acquisition cv therapeutics cash outflows partially offset proceeds million issuances common stock employee stock plans result adoption guidance joint ventures bms january reclassified change noncontrolling interest cash provided operating activities cash used financing activities discussed amended restated credit agreement along whollyowned subsidiary gilead biopharmaceutics ireland corporation may borrow aggregate billion revolving credit loans credit agreement also includes subfacility swingline loans letters credit loans credit agreement bear interest interest rate either libor plus margin ranging percent percent base rate described credit agreement april connection acquisition cv therapeutics borrowed million credit agreement partially fund acquisition fully repaid amount december credit agreement terminate december unpaid borrowings thereunder shall due payable time may reduce commitments may prepay loans credit agreement whole part without penalty subject certain conditions december approximately billion available drawn credit agreement cash used financing activities billion driven primarily billion used repurchase common stock stock repurchase program cash outflows partially offset proceeds million received issuances common stock employee stock plans well million excess tax benefits stock option exercises october board authorized program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means stock repurchase program repurchased shares open market also entered two structured accelerated share repurchase transactions third parties described february october entered accelerated share repurchase agreements financial institution repurchase common stock accelerated basis february transaction paid million settle initial purchase received shares common stock price per share june upon termination agreement received additional shares common stock based average daily volume weightedaverage prices common stock specified period less predetermined discount per share result total number shares repurchased retired accelerated share repurchase agreement shares average purchase price per share october transaction paid million settle initial purchase received shares common stock price per share march upon termination agreement received additional shares common stock based average daily volume weightedaverage prices common stock specified period less predetermined discount per share result total number shares repurchased retired accelerated share repurchase agreement shares average purchase price per share december completed share repurchases billion stock repurchase program january board authorized new program repurchase common stock aggregate amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means stock repurchase plan expire january cash used financing activities million driven primarily million used repurchase common stock stock repurchase program million used pay table contents remaining amounts due term loan partially offset proceeds issuances common stock employee stock plans million distributions noncontrolling interest million well million excess tax benefits stock option exercises believe existing capital resources supplemented cash generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities administrative expenses possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products establishment additional collaborative relationships companies costs associated defense settlement adverse results litigation government investigations may future require additional funding could form proceeds equity debt financings funding required assure available us favorable terms balance sheet arrangements balance sheet arrangements contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december thousands payments due period less one contractual obligations total year years years years convertible senior notes operating lease obligations capital commitments purchase obligations clinical trials total december outstanding principal billion notes issued april december firm capital project commitments approximately million primarily relating enterprise software purchase commitments table contents december firm purchase commitments related active pharmaceutical ingredients certain inventoryrelated items amounts represent minimum purchase requirements actual purchases expected significantly exceed amounts addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures cros although material contracts cros cancelable historically cancelled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts total gross unrecognized tax benefit liabilities million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities amounts included longterm income taxes payable non current deferred tax assets consolidated balance sheet included table recent accounting pronouncements june financial accounting standards board fasb issued amended standards determining whether consolidate variable interest entity accounting standards codification asc section amended standards eliminate mandatory quantitative approach determine whether variable interest gives entity controlling financial interest variable interest entity favor qualitatively focused analysis require ongoing reassessment whether entity primarily beneficiary amended standards effective us beginning first quarter consolidating joint ventures bms primary beneficiary still evaluating whether revised standard impact consolidated financial statements october fasb issued new standards revenue recognition agreements multiple deliverables new standards impact determination individual deliverables included multiple element arrangement may treated separate units accounting additionally new standards modify manner transaction consideration allocated across separately identified deliverables longer permitting residual method allocating arrangement consideration new standards effective us beginning first quarter however early adoption permitted yet evaluated whether new standards material impact consolidated financial statements item quantitative qualitative disclosures market risk foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe australia result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies table contents significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business significant percentage product sales denominated foreign currencies enter foreign currency exchange forward option contracts partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged following table summarizes notional amounts weightedaverage currency exchange rates fair values open foreign currency exchange forward contracts december foreign currency exchange option contracts outstanding december contracts maturities months less weightedaverage rates stated terms amount us dollars per foreign currency fair values represent estimated settlement amounts december notional amounts fair values us dollars thousands foreign currency exchange forward contracts weighted average notional settlement currency amount price fair value euro british pound canadian dollar australian dollar swiss franc danish krone swedish krone norwegian krone new zealand dollar turkish lira total total notional amount billion total fair value relating net liability million open foreign currency exchange forward contracts december compares total notional amount billion total fair value relating net asset million open foreign currency exchange forward option contracts december interest rate risk portfolio availableforsale marketable securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return table contents following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december dollars thousands years ending december total fair value december thereafter total assets availableforsale debt securities average interest rate liabilities convertible senior notes average interest rate april issued notes private placement pursuant rule securities act amended notes issued par bear interest rates notes notes respectively may converted shares common stock subject certain circumstances credit risk portion marketable securities consist auction rate securities began observing failed auctions auction rate securities whose underlying assets comprised student loans december held approximately million auction rate securities within availablefor sale longterm marketable securities whose underlying assets comprised student loans auction rate securities comprised approximately total cash cash equivalents marketable securities december auction rate securities including subject failed auctions currently rated aaa consistent high quality rating required investment policy supported federal government part federal family education loan program overcollateralized auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest auctions continue fail securities invested may unable liquidate auction rate securities par need desire access funds invested securities however based total cash marketable securities position expected operating cash flows well access funds credit facility believe able hold securities recovery auction market related securities may final maturity result anticipate current illiquidity auction rate securities material effect cash requirements working capital light volatility developments seen financial markets continue review cash equivalents marketable securities carefully strive invest prudently believe maintaining primary goals investment policy safety preservation principal diversification risk well liquidity protected us many risks credit markets allowing us continue meet operating cash flow requirements well execute strategic opportunities acquisition cv therapeutics accounts receivable balance december billion compared billion december growth accounts receivable balance due primarily higher product sales antiviral products united states europe european product sales governmentowned supported customers greece italy portugal spain subject significant payment delays due government funding reimbursement practices resulted may continue result increase days sales outstanding due average length time accounts receivable outstanding turn may increase credit risk related certain customers sales customers countries europe tend pay relatively slowly increased may continue increase december table contents accounts receivable greece italy portugal spain totaled million million days past due based contractual payment terms date experienced significant losses respect collection accounts receivable believe accounts receivable net allowances reflected consolidated balance sheets collectible item financial statements supplementary data financial statements required item set forth beginning annual report incorporated herein reference item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission coso based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included annual report issued report effectiveness internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited gilead sciences incs internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso criteria gilead sciences incs management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit conducted audit accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate opinion gilead sciences inc maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states consolidated financial statements gilead sciences inc report dated march expressed unqualified opinion thereon ernst young llp palo alto california march table contents item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings nominees qualification nominees board committees meetings executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance changes waivers code ethics disclosed website intend satisfy disclosure requirement item form k regarding amendment waiver provision code ethics disclosing information website item executive compensation information required item incorporated reference sections proxy statement headings executive compensation compensation committee interlocks insider participation compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference sections proxy statement headings security ownership certain beneficial owners management securities authorized issuance equity compensation plans item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings nominees certain relationships related party transactions item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services table contents part iv item exhibits financial statement schedules following documents filed part annual report index list consolidated financial statements report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements schedule ii included report schedules omitted required required information included financial statements notes thereto exhibits following exhibits filed herewith incorporated reference exhibit exhibit footnote number description document agreement plan merger among registrant apex merger sub inc cv therapeutics inc dated march stockholder agreement registrant louis g lange dated march restated certificate incorporation registrant amended may certificate designation series junior participating preferred stock registrant certificate amendment certificate designation series junior participating preferred stock registrant amended restated bylaws registrant amended restated october reference made exhibit exhibit exhibit exhibit amended restated rights agreement registrant chasemellon shareholder services llc dated october first amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated october second amendment amended restated rights agreement registrant mellon investor services llc formerly known chasemellon shareholder services llc dated may indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april indenture related convertible senior notes due registrant wells fargo bank national association trustee including form convertible senior note due dated april table contents exhibit exhibit footnote number description document confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc convertible note hedge related notes dated april amended restated april registrant bank america na confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring confirmation otc warrant transaction dated april amended restated april registrant bank america na warrants expiring amended restated credit agreement among registrant gilead biopharmaceutics ireland corporation lenders parties thereto bank america na administrative agent swing line lender lc issuer dated december parent guaranty agreement dated december registrant master confirmation registrant citibank na together supplemental confirmation dated october gilead sciences inc stock option plan amended january form option agreements used stock option plan gilead sciences inc nonemployee directors stock option plan amended january form option agreement used gilead sciences inc nonemployee directors stock option plan gilead sciences inc equity incentive plan amended may form employee stock option agreement used equity incentive plan grants prior february form employee stock option agreement used equity incentive plan grants made february april form employee stock option agreement used equity incentive plan grants made may january form employee stock option agreement used equity incentive plan grants commencing february form nonemployee director stock option agreement used equity incentive plan grants prior form nonemployee director option agreement used equity incentive plan initial grants made form nonemployee director option agreement used equity incentive plan annual grants made may form nonemployee director option agreement used equity incentive plan annual grants commencing may form restricted stock agreement used equity incentive plan annual grants nonemployee directors commencing may form restricted stock agreement used equity incentive plan annual grants certain nonemployee directors table contents exhibit exhibit footnote number description document form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form performance share award agreement used equity incentive plan grants made form restricted stock unit issuance agreement used equity incentive plan grants made prior may form restricted stock unit issuance agreement used equity incentive plan grants commencing may gilead sciences inc employee stock purchase plan amended restated november gilead sciences inc international employee stock purchase plan adopted november gilead sciences inc deferred compensation planbasic plan document gilead sciences inc deferred compensation planadoption agreement addendum gilead sciences inc deferred compensation plan gilead sciences inc deferred compensation plan amended restated october gilead sciences inc severance plan amended january gilead sciences inc corporate bonus plan gilead sciences inc code section bonus plan base salaries named executive officers offer letter dated april registrant robin washington form indemnity agreement entered registrant directors executive officers form employee proprietary information invention agreement entered registrant certain officers key employees form employee proprietary information invention agreement entered registrant certain officers key employees revised september amended restated collaboration agreement among registrant gilead holdings llc bristolmyers squibb company er squibb sons llc bristolmyers squibb gilead sciences llc dated september commercialization agreement gilead sciences limited bristolmyers squibb company dated december amendment agreement dated october registrant institute organic chemistry biochemistry iocb rega stichting vzw rega together following exhibits license agreement dated december registrant iocb rega license agreement license agreement dated october registrant iocb rega october license agreement license agreement dated december registrant iocb rega december license agreement table contents exhibit exhibit footnote number description document amendment agreement registrant iocbrega dated december amending license agreement december license agreement sixth amendment agreement license agreement iocbrega registrant dated august amending october license agreement december license agreement development license agreement among registrant f hoffmannla roche ltd hoffmannla roche inc dated september first amendment supplement dated november development licensing agreement registrant f hoffmannla roche ltd hoffmanla roche inc dated september exclusive license agreement registrant successor triangle pharmaceuticals inc glaxo group limited wellcome foundation limited glaxo wellcome inc emory university dated may royalty sale agreement among registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july amended restated license agreement registrant emory university investors trust custodial services ireland limited solely capacity trustee royalty pharma dated july license agreement japan tobacco inc registrant dated march license agreement registrant successor myogen inc abbott deutschland holding gmbh dated october license agreement registrant successor myogen inc abbott laboratories dated june license agreement registrant successor cv therapeutics inc syntex usa inc dated march first amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated july amendment license agreement registrant successor cv therapeutics inc syntex usa inc dated november amendment collaboration license agreement registrant successor cv therapeutics inc roche palo alto llc dated june license collaboration agreement among registrant gilead sciences limited tibotec pharmaceuticals dated july master clinical commercial supply agreement gilead world markets limited registrant patheon inc dated january tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated july addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated may addendum tenofovir disoproxil fumarate manufacturing supply agreement gilead sciences limited pharmachem technologies grand bahama ltd dated december table contents exhibit exhibit footnote number description document tenofovir disoproxil fumarate manufacturing supply agreement registrant ampac fine chemicals llc dated march restated amended toll manufacturing agreement gilead sciences limited registrant altana pharma oranienburg gmbh dated november emtricitabine manufacturing supply agreement gilead sciences limited degussa ag dated june purchase sale agreement escrow instructions electronics imaging inc registrant dated october subsidiaries registrant consent independent registered public accounting firm power attorney reference made signature certification chief executive officer required rule aa rule da securities exchange act amended certification chief financial officer required rule aa rule da securities exchange act amended certifications chief executive officer chief financial officer required rule ab rule db section chapter title united states code usc following materials registrants annual report year ended december formatted extensible business reporting language xbrl includes consolidated balance sheets december ii consolidated statements income years ended december iii consolidated statements cash flows years ended december iv notes consolidated financial statements tagged blocks text filed exhibit registrants current report form k filed march incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed november incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed june incorporated herein reference filed exhibit registrants current report form k filed april incorporated herein reference table contents filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants current report form k also filed december incorporated herein reference filed exhibit registrants current report form k filed october incorporated herein reference filed exhibit registrants registration statement form filed january incorporated herein reference filed exhibit registrants registration statement form amended incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed may incorporated herein reference filed exhibit registrants current report form ka filed february incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit registrants current report form k first filed december incorporated herein reference filed exhibit registrants registration statement form filed december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference information included registrants current report form k filed february incorporated herein reference filed exhibit registrants quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended march incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference table contents filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit triangle pharmaceuticals incs quarterly report form qa filed november incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants quarterly report form q quarter ended march incorporated herein reference filed exhibit myogen incs registration statement form amended originally filed august incorporated herein reference filed exhibit cv therapeutics incs registration statement form amended originally filed april incorporated herein reference filed exhibit cv therapeutics incs quarterly report form q quarter ended june incorporated herein reference filed exhibit registrants quarterly report form q quarter ended september incorporated herein reference filed exhibit registrants annual report fiscal year ended december incorporated herein reference filed exhibit registrants current report form k filed august incorporated herein reference management contract compensatory plan arrangement certification accompanies relates deemed filed securities exchange commission incorporated reference filing registrant securities act amended securities exchange act amended whether made date irrespective general incorporation language contained filing xbrl information furnished filed part registration statement prospectus purposes sections securities act amended deemed filed purposes section securities exchange act amended otherwise subject liability sections certain confidential portions exhibit omitted means marking portions asterisk mark exhibit filed separately secretary securities exchange commission without mark pursuant registrants application requesting confidential treatment rule b securities exchange act amended table contents gilead sciences inc consolidated financial statements years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements table contents report independent registered public accounting firm board directors stockholders gilead sciences inc audited accompanying consolidated balance sheets gilead sciences inc december related consolidated statements income stockholders equity cash flows three years period ended december audits also included financial statement schedule listed index item financial statements schedule responsibility companys management responsibility express opinion financial statements schedule based audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement audit includes examining test basis evidence supporting amounts disclosures financial statements audit also includes assessing accounting principles used significant estimates made management well evaluating overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statements referred present fairly material respects consolidated financial position gilead sciences inc december consolidated results operations cash flows three years period ended december conformity us generally accepted accounting principles also opinion related financial statement schedule considered relation basic financial statements taken whole presents fairly material respects information set forth therein discussed notes consolidated financial statements company changed method accounting convertible senior notes may settled cash upon conversion method accounting presentation noncontrolling interest method accounting business combinations effective january also audited accordance standards public company accounting oversight board united states gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission report dated march expressed unqualified opinion thereon ernst young llp palo alto california march table contents gilead sciences inc consolidated balance sheets thousands except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances december december inventories deferred tax assets prepaid taxes prepaid expenses current assets total current assets property plant equipment net noncurrent portion prepaid royalties noncurrent deferred tax assets longterm marketable securities intangible assets noncurrent assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued compensation employee benefits income taxes payable accrued liabilities deferred revenues current portion longterm obligations total current liabilities longterm deferred revenues convertible senior notes net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share shares authorized shares issued outstanding december respectively additional paidin capital accumulated comprehensive income loss retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes table contents gilead sciences inc consolidated statements income thousands except per share amounts year ended december revenues product sales royalty revenues contract revenues total revenues costs expenses cost goods sold research development selling general administrative purchased inprocess research development total costs expenses income operations interest income net interest expense income provision income taxes provision income taxes net income net loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholdersbasic shares used per share calculationbasic net income per share attributable gilead common stockholdersdiluted shares used per share calculationdiluted see accompanying notes table contents gilead sciences inc consolidated statements stockholders equity thousands gilead stockholders equity common stock accumulated retained additional earnings total paidin comprehensive accumulated noncontrolling stockholders shares amount capital income loss deficit interest equity balance december adoption new accounting guidance income taxes distributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions repurchases common stock balance december distributions noncontrolling interest net income loss unrealized loss availableforsale securities net tax foreign currency translation adjustment unrealized gain cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions repurchases common stock balance december distributions noncontrolling interest net income loss unrealized gain availableforsale securities net tax foreign currency translation adjustment unrealized loss cash flow hedges net tax comprehensive income issuances employee stock purchase plan stock option exercises net tax benefits employee stock plans compensatory stock transactions assumption stock options connection acquisition repurchases common stock balance december see accompanying notes table contents gilead sciences inc consolidated statements cash flows thousands year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization purchased inprocess research development expense stockbased compensation expenses excess tax benefits stockbased compensation tax benefits employee stock plans deferred income taxes noncash transactions changes operating assets liabilities accounts receivable net inventories prepaid expenses assets accounts payable income taxes payable accrued liabilities deferred revenues net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities acquisitions net cash acquired purchases nonmarketable equity securities capital expenditures net cash used investing activities financing activities proceeds issuances common stock proceeds credit facility repayment credit facility repurchases common stock extinguishment longterm debt repayments longterm debt obligations excess tax benefits stockbased compensation distributions noncontrolling interest net cash used financing activities effect exchange rate changes cash net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid income taxes paid see accompanying notes table contents gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june biopharmaceutical company discovers develops commercializes innovative therapeutics areas unmet medical need mission advance care patients suffering life threatening diseases worldwide headquartered foster city california operations north america europe australia currently market truvada emtricitabinetenofovir disoproxil fumarate atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate mg viread tenofovir disoproxil fumarate emtriva emtricitabine treatment human immunodeficiency virus infection hepsera adefovir dipivoxil viread treatment chronic hepatitis b ambisome amphotericin b liposome injection treatment severe fungal infections letairis ambrisentan treatment pulmonary arterial hypertension pah ranexa ranolazine treatment chronic angina vistide cidofovir injection treatment cytomegalovirus infection cayston aztreonam inhalation solution treatment improve respiratory symptoms cystic fibrosis cf patients pseudomonas aeruginosa p aeruginosa f hoffmannla roche ltd together hoffmannla roche inc roche markets tamiflu oseltamivir phosphate treatment prevention influenza royaltypaying collaborative agreement us osi pharmaceuticals inc markets macugen pegaptanib sodium injection united states europe treatment neovascular agerelated macular degeneration royaltypaying collaborative agreement us glaxosmithkline inc gsk markets volibris ambrisentan outside united states treatment pah royaltypaying collaborative agreement us menarini international operations luxembourg sa menarini markets ranexa outside united states royaltypaying collaborative agreement us astellas us llc markets lexiscan regadenoson injection united states use pharmacologic stress agent radionuclide myocardial perfusion imaging mpi royaltypaying collaborative agreement us basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries joint ventures bristol myers squibb company bms primary beneficiary record noncontrolling interest consolidated financial statements reflect bmss interest joint ventures significant intercompany transactions eliminated consolidated financial statements include results companies acquired us date acquisition applicable reporting periods fasb accounting standards codification july adopted financial accounting standards board fasb accounting standards codification asc fasb asc became source authoritative us generally accepted accounting principles gaap recognized fasb applied nongovernmental entities effective interim periods fiscal years ending september result majority historically issued accounting pronouncements superseded fasb asc convertible senior notes january adopted guidance convertible senior notes due notes convertible senior notes due notes collectively notes retrospective basis guidance requires us bifurcate conversion option debt instrument classifying conversion option table contents gilead sciences inc notes consolidated financial statementscontinued equity accreting resulting discount debt additional interest expense expected life debt result retrospective adoption guidance reflected additional interest expense million million respectively related benefit income taxes million million respectively decrease net income per share attributable gilead common stockholders diluted basis respectively years ended december recorded additional interest expense million related benefit income taxes million decrease net income per share attributable gilead common stockholders diluted basis approximately year ended december addition retrospective adoption guidance decreased deferred tax assets debt issuance costs included assets aggregate million decreased convertible senior notes net included longterm liabilities million increased total stockholders equity million charge million retained earnings consolidated balance sheet december see note additional information noncontrolling interest january adopted guidance joint ventures bms retrospective basis guidance establishes accounting reporting standards ownership interests subsidiaries held parties parent amount consolidated net income loss attributable parent noncontrolling interests changes parents ownership interest valuation retained noncontrolling equity investments subsidiary deconsolidated guidance also establishes additional reporting requirements identify distinguish ownership interest parent interest noncontrolling owners guidance effective interim periods fiscal years beginning december requires retrospective application periods presented result retrospective adoption guidance reclassified noncontrolling interest formerly minority interest liabilities stockholders equity consolidated balance sheets adoption guidance also resulted reclassification change noncontrolling interest net cash provided operating activities net cash used financing activities consolidated statements cash flows also presented noncontrolling interest consolidated statements income net loss attributable noncontrolling interest component consolidated net income retrospective basis significant accounting policies estimates judgments preparation consolidated financial statements conformity us gaap requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis management evaluates estimates including critical accounting policies estimates related revenue recognition intangible assets allowance doubtful accounts prepaid royalties clinical trial accruals tax provision stockbased compensation base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition product sales recognize revenue product sales persuasive evidence arrangement exists delivery customer occurred price fixed determinable collectability reasonably assured upon recognition revenue product sales provisions made government rebates medicaid table contents gilead sciences inc notes consolidated financial statementscontinued reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate items deducted gross product sales government rebates estimate reductions revenues governmentmanaged medicaid programs well certain qualifying federal state foreign government programs based contractual terms historical utilization rates new information regarding changes programs regulations guidelines would impact amount actual rebates expectations regarding future utilization rates programs us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements government rebates invoiced directly us recorded accrued liabilities consolidated balance sheets qualified programs purchase products wholesalers lower contractual government price wholesalers charge back us difference acquisition cost lower contractual government price record allowances accounts receivable cash discounts estimate cash discounts based contractual terms historical utilization rates expectations regarding future utilization rates distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return permit returns product damaged defective received customer case product sold unites states certain international countries product expired accept returns product expire within six months prior expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns royalty revenues royalty revenue sales lexiscan ambisome astellas pharma us inc astellas recognized month following month corresponding sales occur royalty revenue sales products generally recognized received generally quarter following quarter corresponding sales occur contract revenues revenue nonrefundable upfront license fees milestone payments development collaboration obligation supply product recognized performance occurs obligations table contents gilead sciences inc notes consolidated financial statementscontinued completed accordance specific terms gileads obligations arrangements revenue recognized obligation fulfilled ratably development manufacturing period revenue associated substantive atrisk milestones recognized based upon achievement milestones defined respective agreements advance payments received excess amounts earned classified deferred revenue consolidated balance sheets shipping handling costs shipping handling costs incurred inventory purchases product shipments recorded cost goods sold consolidated statements income research development expenses major components research development rd expenses consist personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees overhead allocations consisting various support facilities related costs rd activities also separated three main categories research clinical development pharmaceutical development research costs typically consist preclinical toxicology costs clinical development costs include costs phase clinical trials pharmaceutical development expenses consist costs product formulation chemical analysis charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed third party cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies reflect level effort actually incurred cro material cro contracts terminable us upon written notice generally liable actual effort expended cro certain noncancelable expenses incurred point termination amounts paid advance related uncompleted services refunded us contract terminated contracts may include additional termination payments become due payable terminate contract additional termination payments recorded becomes probable contract terminated advertising expenses expense costs advertising including promotional expenses incurred advertising expenses million million million net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potential dilutive shares common stock resulting assumed exercise outstanding stock options equivalents consisting primarily performance shares assumed exercise warrants relating notes determined treasury stock method table contents gilead sciences inc notes consolidated financial statementscontinued principal amount notes settled cash conversion spread relating notes included calculation diluted net income per share attributable gilead common stockholders common stock resulting assumed settlement conversion spread notes dilutive effect average market price common stock period exceeds conversion prices notes notes respectively years ended average market price common stock exceeded conversion prices notes dilutive effect included table warrants relating notes notes dilutive effect average market price common stock period exceeds warrants exercise prices respectively average market price common stock years ended december exceed warrants exercise prices relating notes stock options purchase approximately million million million weightedaverage shares common stock outstanding years ended december respectively included computation diluted net income per share attributable gilead common stockholders options exercise prices greater average market price common stock periods therefore effect antidilutive following table reconciliation numerator denominator used calculation basic diluted net income per share attributable gilead common stockholders thousands year ended december numerator net income attributable gilead denominator weightedaverage shares common stock outstanding used calculation basic net income per share attributable gilead common stockholders effect dilutive securities stock options equivalents conversion spread related notes conversion spread related notes weightedaverage shares common stock outstanding used calculation diluted net income per share attributable gilead common stockholders stockbased compensation january adopted guidance sharebased payments employees directors including grants stock options guidance requires sharebased payments employees recognized consolidated statements income based fair values guidance also requires benefit tax deductions excess recognized compensation cost reported consolidated statements cash flows financing activity rather operating activity applied modified prospective method requires compensation expenses recorded vesting nonvested stock options stockbased awards beginning first quarter adoption addition calculated pool excess tax benefits available within additional paidin capital apic accordance provisions guidance table contents gilead sciences inc notes consolidated financial statementscontinued cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents may enter overnight repurchase agreements repos purchase securities obligation resell following day securities purchased agreements resell recorded face value reported cash cash equivalents investment policy may enter repos major banks authorized dealers provided repos collateralized us government securities fair value least fair value securities sold us eligible instruments investment policy included cash equivalents include commercial paper money market funds bank obligations marketable nonmarketable securities determine appropriate classification marketable securities consist primarily debt securities include auction rate securities variable rate demand obligations time purchase reevaluate designation balance sheet date marketable securities considered availableforsale carried estimated fair values reported either cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale securities excluded net income reported accumulated comprehensive income loss separate component stockholders equity interest income net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline result entering collaborations time time may hold investments nonpublic companies record nonmarketable securities cost noncurrent assets less amounts otherthantemporary impairment regularly review securities indicators impairment investments nonmarketable securities material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe certain countries payments typically slow primarily greece italy portugal spain aggregated accounts receivable balance significant cases slow payment practices countries reflect pace governmental entities reimburse customers turn may increase financial risk related table contents gilead sciences inc notes consolidated financial statementscontinued certain customers sales customers countries europe tend pay relatively slowly increased may continue increase december aggregate accounts receivable greece italy portugal spain totaled million million days past due based contractual payment terms date experienced significant losses respect collection accounts receivable believe past due accounts receivable net allowances reflected consolidated balance sheets collectible certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application nda filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government rebate programs cash discounts prompt payment doubtful accounts sales returns estimates wholesaler chargebacks government rebates cash discounts sales returns based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding customer geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant consistent managements expectations inventories inventories recorded lower cost market cost determined firstin firstout basis periodically review composition inventories order identify obsolete slowmoving otherwise unsaleable items unsaleable items observed alternate uses inventory record writedown net realizable value period impairment first recognized prepaid royalties prepaid royalties capitalized cost initially equivalent present value future royalty obligation would expect pay licensor expected future levels product sales incorporating related technology review periodically expected future sales levels products indicators might require writedown net recoverable value asset change estimated life prepaid royalty amortize prepaid royalties cost goods sold remaining life underlying patent based effective royalty rate derived forecasted future product sales incorporating related technology review effective royalty rate least annually prospectively adjust effective rate based significant new facts circumstances may arise review prepaid royalties primarily comprised emtricitabine royalties paid emory university emory hiv indication royalty pharma purchased royalty interest owned emory terms transaction royalty pharma paid respectively total table contents gilead sciences inc notes consolidated financial statementscontinued purchase price million emory exchange elimination emtricitabine royalties due emory worldwide net sales products containing emtricitabine result transaction capitalized prepaid royalties share million purchase price million december unamortized prepaid royalty asset million million respectively million million million amortized cost goods sold respectively property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years follows description estimated useful life buildings improvements laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term office computer equipment includes capitalized software unamortized capitalized software costs million million consolidated balance sheets december respectively leasehold improvements capitalized leased equipment amortized shorter lease term assets useful life amortization capitalized leased equipment included depreciation expense capitalized interest construction inprogress included property plant equipment interest capitalized significant goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets primarily related marketed products purchased inprocess research development iprd projects acquisition cv therapeutics inc cv therapeutics april measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value assets carrying amounts intangible assets finite useful lives amortized estimated useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable amortizing intangible asset related ranexa product acquired cv therapeutics estimated useful life using amortization rate derived forecasted future product sales ranexa product sales forecasts prepared annually determined using best estimates future activity upon considering factors historical expected future patient usage uptake products introduction complimentary combination therapies products future product launch plans previously unanticipated significant change occurs sales forecasts prospectively update rate used amortize intangible asset related ranexa may increase future cost goods sold record amortization expense amortizing intangible asset related lexiscan table contents gilead sciences inc notes consolidated financial statementscontinued product also acquired cv therapeutics estimated useful life cost goods sold straightline basis given current lexiscan revenues consist royalties received collaboration partner limited ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate utilizing forecasted product sales approach impairment longlived assets carrying value longlived assets reviewed regular basis existence facts circumstances internally externally may suggest impairment specific potential indicators impairment include significant decrease fair value asset significant change extent manner asset used significant physical change asset significant adverse change legal factors business climate affects value asset adverse action assessment fda another regulator accumulation costs significantly excess amount originally expected acquire construct asset operating cash flow losses combined history operating cash flow losses projection forecast demonstrates continuing losses associated income producing asset indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset asset group eventual disposition carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transactions contracts adjustments resulting translating financial statements foreign subsidiaries us dollars excluded determination net income recorded accumulated comprehensive income loss separate component stockholders equity net foreign currency exchange transaction gains losses included interest income net consolidated statements income net transaction gains losses totaled million million million respectively hedge certain foreign currency exposures related outstanding monetary assets liabilities forecasted product sales foreign currency exchange forward contracts foreign currency exchange option contracts general market risks contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time limit risk counterparties contracts may unable perform transacting major banks monitor closely context current market conditions also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter speculative foreign currency transactions hedge net investment foreign subsidiaries fair value financial instruments financial instruments consist principally cash cash equivalents marketable securities accounts receivable foreign currency exchange forward option contracts accounts payable longterm debt cash cash equivalents marketable securities foreign currency exchange contracts hedge accounts receivable forecasted sales reported respective fair values consolidated balance sheets carrying value fair value notes billion billion respectively table contents gilead sciences inc notes consolidated financial statementscontinued december carrying value fair value notes billion billion respectively december fair value notes based quoted market values remaining financial instruments reported consolidated balance sheets amounts approximate current fair values income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations existing tax laws regulations various factors may favorable unfavorable effects income tax rate factors include limited interpretations existing tax laws changes tax laws rates accounting stock options sharebased payments mergers acquisitions future levels rd spending changes accounting standards changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits impact income tax provision resulting mentioned factors may significant could negative impact consolidated net income record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return believe uncertain tax positions currently pending material adverse effect consolidated financial statements although adverse resolution one uncertain tax positions period could material impact results operations period recent accounting pronouncements june fasb issued amended standards determining whether consolidate variable interest entity asc section amended standards eliminate mandatory quantitative approach determine whether variable interest gives entity controlling financial interest variable interest entity favor qualitatively focused analysis require ongoing reassessment whether entity primarily beneficiary amended standards effective us beginning first quarter consolidating joint ventures bms primary beneficiary still evaluating whether revised standard impact consolidated financial statements october fasb issued new standards revenue recognition agreements multiple deliverables new standards impact determination individual deliverables included multiple element arrangement may treated separate units accounting additionally new standards modify manner transaction consideration allocated across separately identified deliverables longer permitting residual method allocating arrangement consideration new standards effective us beginning first quarter however early adoption permitted yet evaluated whether new standards material impact consolidated financial statements fair value measurements january adopted guidance fair value measurements prospective basis financial assets liabilities well nonfinancial assets liabilities recognized disclosed table contents gilead sciences inc notes consolidated financial statementscontinued fair value recurring basis guidance defines fair value establishes framework measuring fair value expands disclosure requirements regarding fair value measurements guidance effective fiscal years beginning november financial assets liabilities well nonfinancial assets liabilities recognized disclosed fair value recurring basis financial statements effective fiscal years beginning november nonfinancial assets liabilities january adopted provisions guidance prospective basis non financial assets liabilities recognized disclosed fair value recurring basis adoption guidance effect consolidated net income year ended december fair value guidance requires determine fair value financial nonfinancial assets liabilities using fair value hierarchy established guidance describes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques well significant management judgment estimation following table summarizes assets liabilities recorded fair value respective fair value classification level input within fair value hierarchy defined thousands december december level level level total level level level total assets debt securities us treasury securities us government sponsored entity debt securities municipal debt securities corporate debt securities residential mortgagebacked securities student loanbacked securities debt securities total debt securities equity securities derivatives liabilities derivatives table contents gilead sciences inc notes consolidated financial statementscontinued marketable securities measured fair value using level inputs primarily comprised us government sponsored corporate debt securities company reviews trading activity pricing investments measurement date sufficient quoted pricing identical securities available company uses market pricing observable market inputs similar securities obtained various third party data providers inputs represent quoted prices similar assets active markets inputs derived observable market data approach results classification securities level fair value hierarchy following table reconciliation marketable securities measured fair value using significant unobservable inputs level thousands year ended december balance beginning period total realized unrealized gains losses included interest income net comprehensive income net sales marketable securities transfers level balance end period total losses included interest income net attributable change unrealized losses relating assets still held reporting date marketable securities measured fair value using level inputs substantially comprised auction rate securities within availableforsale investment portfolio underlying assets auction rate securities comprised student loans although auction rate securities would typically measured using level inputs failure auctions lack market activity liquidity experienced since beginning required securities measured using level inputs fair value auction rate securities determined using discounted cash flow model considered projected cash flows issuing trusts underlying collateral expected yields projected cash flows estimated based underlying loan principal bonds outstanding payout formulas weightedaverage life cash flows projected considered collateral composition securities related historical projected prepayments underlying student loans weightedaverage expected life four eight years discount rates used discounted cash flow model based market conditions comparable similar term assetbacked securities well fixed income securities adjusted illiquidity discount resulting annual discount rate auction rate securities reset every seven days maturity dates ranging annual interest rates ranging december auction rate securities continued earn interest april fasb also issued additional guidance estimating fair value volume level activity asset liability significantly decreased relation normal market activity asset liability applicable valuation auction rate securities held us active market december auction rate securities recorded longterm marketable securities consolidated balance sheets december although continued failed auctions well lack market activity liquidity believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis table contents gilead sciences inc notes consolidated financial statementscontinued availableforsale securities following table summary availableforsale debt equity securities recorded cash equivalents marketable securities consolidated balance sheets estimated fair values availableforsale securities generally based prices obtained commercial pricing services thousands gross gross amortized unrealized unrealized estimated cost gains losses fair value december debt securities us treasury securities us government sponsored entity debt securities municipal debt securities corporate debt securities residential mortgagebacked securities student loanbacked securities debt securities total debt securities equity securities total december debt securities us treasury securities us government sponsored entity debt securities municipal debt securities corporate debt securities residential mortgagebacked securities student loanbacked securities debt securities total debt securities equity securities total december debt securities consisted primarily foreign government agency securities well assetbacked securities following table summarizes classification availableforsale debt equity securities consolidated balance sheets thousands december december cash cash equivalents shortterm marketable securities longterm marketable securities total table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes portfolio availableforsale debt securities contractual maturity thousands december december amortized amortized cost fair value cost fair value less one year greater one year less five years greater five years less ten years greater ten years total following table summarizes gross realized gains losses related sales marketable securities thousands year ended december gross realized gains sales gross realized losses sales cost securities sold determined based specific identification method following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired thousands less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december debt securities us treasury securities us government sponsored entity debt securities municipal debt securities corporate debt securities residential mortgagebacked securities student loanbacked securities debt securities total december debt securities us treasury securities us government sponsored entity debt securities municipal debt securities corporate debt securities residential mortgagebacked securities student loanbacked securities debt securities total table contents gilead sciences inc notes consolidated financial statementscontinued december gross unrealized losses primarily result increase yieldtomaturity underlying securities approximately respectively total number securities unrealized loss position case auction rate securities gross unrealized losses caused higher discount rate used valuation securities compared coupon rates securities significant facts circumstances arisen indicate deterioration creditworthiness issuers securities based review securities believe otherthantemporary impairments securities december intend sell securities likely required sell securities recovery amortized cost basis derivative financial instruments january adopted guidance derivative instruments prospective basis requires enhanced qualitative quantitative disclosures enable financial statement users better understand effects derivatives hedging entitys financial position financial performance cash flows context entitys risk exposures operate foreign countries exposes us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies significant euro order manage risk related changes foreign currency exchange rates hedge certain foreign currency exposures related outstanding monetary assets liabilities forecasted product sales foreign currency exchange forward contracts foreign currency exchange option contracts general market risks foreign currency exchange contracts offset corresponding gains losses transactions hedged exposure credit risk contracts function changes interest currency exchange rates therefore varies time limit risk counterparties contracts may unable perform transacting major banks monitor closely context current market conditions also limit risk loss entering contracts provide net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative financial contracts trading purposes hedge net investment foreign subsidiaries enter foreign currency exchange contracts hedge market risk exposure associated foreign currency exchange rate fluctuations certain monetary assets liabilities foreign subsidiaries denominated nonfunctional currency derivative instruments designated hedges record changes fair value instruments interest income net consolidated statements income foreign currency exchange contracts used hedge forecasted product sales designated cash flow hedges derivative instruments employed eliminate minimize certain foreign currency exposures confidently identified quantified maturities months less inception hedging relationship quarterly basis assess hedge effectiveness prospective basis performing regression analysis taking change cash flow underlying contract regressing change cash flow hedge instrument assess hedge effectiveness retrospective basis using dollar offset approach monthly exclude time value effectiveness testing recognize changes time value hedge interest income net effective component hedge recorded accumulated comprehensive income oci within stockholders equity unrealized gain loss hedging instrument hedged forecasted transactions occur hedges dedesignated table contents gilead sciences inc notes consolidated financial statementscontinued unrealized gains losses reclassified product sales majority gains losses related hedged forecasted transactions reported accumulated oci december reclassified product sales within months notional amounts foreign currency exchange forward option contracts outstanding billion billion december respectively following table summarizes information fair values derivative instruments consolidated balance sheet december thousands december asset derivatives liability derivatives location fair value location fair value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts noncurrent assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated statement income year ended december thousands year ended december derivatives designated hedges net losses recognized oci effective portion net gains reclassified accumulated oci product sales effective portion net losses recognized interest income net ineffective portion amounts excluded effectiveness testing derivatives designated hedges net losses recognized interest income net acquisitions cv therapeutics inc january adopted guidance recognizing measuring assets acquired liabilities assumed noncontrolling interests acquiree business combination guidance also provides clarification recognizing measuring goodwill acquired business combination requires iprd table contents gilead sciences inc notes consolidated financial statementscontinued capitalized fair value intangible assets time acquisition requires acquisitionrelated expenses restructuring costs recognized separately business combination expands definition constitutes business requires acquirer disclose information users may need evaluate understand financial effect business combination adopted provisions guidance prospective basis applied acquisition cv therapeutics discussed april acquired cv therapeutics cash tender offer terms agreement plan merger entered march cv therapeutics publiclyheld biopharmaceutical company based palo alto california primarily focused discovery development commercialization small molecule drugs treatment cardiovascular metabolic pulmonary diseases cv therapeutics two marketed products ranexa treatment chronic angina lexiscan injection use pharmacologic stress agent radionuclide mpi patients unable undergo adequate exercise stress cv therapeutics also several product candidates clinical development treatment cardiovascular metabolic pulmonary diseases believe acquisition provide us opportunity expand cardiovascular therapeutic area cv therapeutics acquisition accounted business combination results operations cv therapeutics since april included consolidated statement income significant acquisition date determined april date acquired approximately outstanding shares common stock cv therapeutics obtained effective control company acquisition completed two days later april time cv therapeutics became whollyowned subsidiary aggregate consideration transferred acquire cv therapeutics billion consisted cash paid common stock equity instruments prior closing billion fair value vested stock options assumed million accordance merger agreement number gilead stock options restricted stock units assumed cv therapeutics stock options restricted stock units converted determined based option conversion ratio conversion ratio calculated taking per share acquisition price dividing average closing price common stock five consecutive trading days immediately preceding including closing date april per share fair value stock options assumed calculated using blackscholes valuation model following assumptions market price per share closing price common stock acquisition date expected term ranging years riskfree interest rate ranging expected volatility ranging dividend yield fair value restricted stock units assumed calculated using acquisitiondate closing price per share common stock included fair value vested stock options assumed us million consideration transferred acquisition vested restricted stock units assumed us estimated fair value unvested stock options restricted stock units assumed us million included consideration transferred recognized stockbased compensation expenses remaining future vesting period awards table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes assets acquired liabilities assumed april thousands intangible assetsmarketed products intangible assetsiprd goodwill deferred tax assets deferred tax liabilities assetsliabilities cash cash equivalents marketable securities accounts receivable inventories prepaids current assets property plant equipment assets accounts payable accrued current liabilities convertible senior notes liabilities total net liabilities total consideration transferred fourth quarter recorded balance sheet reclassification reduced intangible assets related iprd million reduced deferred tax liabilities million increased goodwill million reclassification resulted discovery information affected initial valuation certain iprd intangible assets acquired cv therapeutics intangible assets substantial portion assets acquired consisted intangible assets related cv therapeutics two marketed products ranexa lexiscan cv therapeutics iprd projects management determined estimated acquisitiondate fair values intangible assets related marketed products iprd projects million million respectively million intangible assets related marketed products million related ranexa million related lexiscan determined intangible assets finite useful lives amortized respective useful lives estimated periods associated product patents expire periods intangible assets expected contribute future cash flows related products amortizing intangible asset related ranexa estimated useful life using amortization rate derived forecasted future product sales ranexa amortizing intangible asset related lexiscan estimated useful life straightline basis given current lexiscan revenues consist royalties received collaboration partner limited ongoing access visibility partners future sales forecasts make reasonable estimate amortization rate utilizing forecasted product sales approach weightedaverage amortization period intangible assets approximately ten years table contents gilead sciences inc notes consolidated financial statementscontinued million intangible assets related iprd projects million related gs formerly cvt product candidate phase clinical studies treatment hypertriglyceridemia remaining balance intangible assets related iprd projects represented various process projects single project comprising significant portion total value intangible assets related iprd projects considered indefinite lived completion abandonment associated rd efforts period assets considered indefinitelived amortized tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value iprd projects respective carrying amounts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time estimated fair value intangible assets related marketed products iprd projects determined using income approach discounts expected future cash flows present value estimated fair value intangible assets using present value discount rate based estimated weightedaverage cost capital companies profiles substantially similar cv therapeutics comparable estimated internal rate return cv therapeutics operations represents rate market participants would use value intangible assets intangible assets related iprd projects compensated differing phases development project probabilityadjusting estimation expected future cash flows associated project determined present value expected future cash flows using discount rate projected cash flows iprd projects based key assumptions estimates revenues operating profits related projects considering stages development time resources needed complete development approval related product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing drug compound obtaining marketing approval fda regulatory agencies risks related viability potential alternative treatments future target markets deferred tax assets deferred tax liabilities million deferred tax assets resulting acquisition primarily related federal state net operating loss tax credit carryforwards million deferred tax liabilities resulting acquisition primarily related difference book basis tax basis intangible assets related marketed products iprd projects concluded likely realize benefit deferred tax assets related certain state net operating loss carryforwards result valuation allowance million recorded related deferred tax assets presentation purposes million deferred tax liabilities noncurrent nature netted noncurrent deferred tax assets consolidated balance sheet convertible senior notes result acquisition assumed convertible notes cv therapeutics consisting senior subordinated convertible notes due senior subordinated convertible notes due senior subordinated convertible debentures due convertible notes recognized fair values acquisition date may offered repurchase convertible notes consideration par value plus accrued interest required terms respective convertible note agreements following occurrence change control fundamental change defined agreements december substantially convertible notes extinguished table contents gilead sciences inc notes consolidated financial statementscontinued goodwill excess consideration transferred fair values assigned assets acquired liabilities assumed million represents goodwill amount resulting acquisition management believes goodwill mainly represents synergies economies scale expected combining operations cv therapeutics none goodwill expected deductible income tax purposes recorded goodwill intangible asset consolidated balance sheet acquisition date goodwill tested impairment annual basis annual tests become aware events occurring changes circumstances would indicate reduction fair value goodwill carrying amount acquisitionrelated transaction costs restructuring expenses recognized million acquisitionrelated transaction costs selling general administrative sga expenses year ended december consisted primarily investment banker fees legal accounting costs related acquisition addition second quarter approved plan realize certain synergies cv therapeutics us realign cardiovascular operations eliminate certain redundancies restructuring plan included consolidation realignment cardiovascular rd organization exit certain facilities termination certain contractual obligations result restructuring plan recorded million million sga expenses rd expenses respectively primarily related employee severance relocation termination benefits lease termination costs facilitiesrelated expenses expect incur additional million bringing total amount incurred connection significant activities restructuring plan approximately million employee severance relocation termination benefits million facilitiesrelated expenses following table summarizes restructuring liabilities accrued changes amounts period thousands employee severance facilities termination related benefits costs balance december costs incurred period costs paid settled period balance december pro forma information following unaudited pro forma information presents combined results operations gilead cv therapeutics acquisition cv therapeutics completed january respectively adjustments give effect pro forma events directly attributable acquisition unaudited pro forma results reflect operating efficiencies potential cost savings may result consolidation operations gilead cv therapeutics accordingly unaudited pro forma results presented illustrative purposes intended represent indicative actual results operations combined company would achieved acquisition occurred beginning period presented intended represent indicative future results operations table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes unaudited pro forma results operations thousands year ended december total revenues net income attributable gilead navitas assets llc may executed asset purchase agreement navitas assets llc navitas acquire assets related cicletanine business acquired exclusive rights regulatory data filings development cicletanine monotherapy pah indications united states evaluating cicletanine currently phase clinical trials potential treatment pah aggregate consideration transferred acquisition million consisted primarily cash paid addition navitas entitled potential additional purchase consideration including payments contingent future achievement certain development regulatory milestones amounts recorded related contingencies resolved consideration transferred allocated iprd represents purchased iprd program cicletanine yet reached technological feasibility alternative future uses acquisition date therefore expensed upon acquisition within consolidated statement income nycomed limited september completed acquisition nycomed limited nycomed whollyowned irish subsidiary germanybased pharmaceutical company nycomed gmbh nycomed facility located cork ireland conducted manufacturing tableting operations nycomed gmbh transferred certain manufacturing operations dublin ireland area site facility utilize site primarily solid dose tablet manufacturing existing future products well product packaging nycomed acquisition accounted business combination results operations nycomed since acquisition date included consolidated statements income aggregate consideration transferred nycomeds common stock million consisted cash paid closing million estimated direct transaction costs million employeerelated severance costs million employeerelated severance costs capitalized part purchase price established workforce reduction plan part acquisition transaction costs fully paid consideration transferred allocated primarily property plant equipment million remaining balance allocated net working capital connection transfer certain manufacturing operations dublin ireland area site cork facility finalized personnel plan respect dublin employees recognized onetime termination benefits million fourth quarter table contents gilead sciences inc notes consolidated financial statementscontinued inventories inventories summarized follows thousands december raw materials work process finished goods total inventories december joint ventures formed gilead bms see note included consolidated financial statements held million million inventory respectively efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz property plant equipment property plant equipment summarized follows thousands december property plant equipment net buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment capitalized leased equipment construction progress subtotal less accumulated depreciation amortization including relating capitalized leased equipment respectively subtotal land total january completed purchase office building approximately acres land located foster city california aggregate purchase price million based estimated relative fair values purchase price allocated primarily land million building million land improvements million office furniture equipment million table contents gilead sciences inc notes consolidated financial statementscontinued intangible assets following table summarizes carrying amount intangible assets thousands december goodwill finite lived intangible assets indefinite lived intangible assets total following table summarizes changes carrying amount goodwill thousands balance december goodwill resulting acquisition cv therapeutics balance december following table summarizes finitelived intangible assets thousands december december gross gross carrying accumulated carrying accumulated amount amortization amount amortization intangible assetranexa intangible assetlexiscan total amortization expense related intangible assets million year ended december recorded primarily cost goods sold consolidated statement income amortization expense related intangible assets million million years ended december respectively recorded primarily sga expenses consolidated statements income december estimated future amortization expense associated intangible assets five succeeding fiscal years follows thousands fiscal year amount total december indefinitelived intangible assets million related purchased iprd acquisition cv therapeutics table contents gilead sciences inc notes consolidated financial statementscontinued collaborative arrangements result entering strategic collaborations time time may hold investments nonpublic companies review interests investee companies consolidation andor appropriate disclosure based applicable guidance december determined certain investee companies variable interest entities however respect joint ventures bms primary beneficiary therefore consolidate investees bristolmyers squibb company north america december entered collaboration bms united states develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz sell atripla collaboration structured joint venture operates limited liability company named bristol myers squibb gilead sciences llc consolidate ownership interests joint venture thus sharing product revenue costs reflect respective economic interests bms us based proportions net selling price atripla attributable efavirenz truvada since net selling price truvada may change time relative net selling price efavirenz bmss respective economic interests joint venture may vary annually share marketing sales efforts bms parties obligated provide equivalent sales force efforts minimum number years responsible accounting financial reporting tax reporting product distribution joint venture parties provide respective bulk active pharmaceutical ingredients joint venture approximate market values july joint venture received approval fda sell atripla united states september bms amended joint ventures collaboration agreement allow joint venture sell atripla canada october joint venture received approval health canada sell atripla canada december joint venture held efavirenz active pharmaceutical ingredient purchased bms bmss estimated net selling price efavirenz us market amounts included inventories consolidated balance sheets december total assets held joint venture billion billion respectively consisted primarily cash cash equivalents accounts receivable including intercompany receivables gilead inventories december total liabilities held joint venture billion million respectively consisted primarily accounts payable including intercompany payables gilead accrued expenses asset liability amounts reflect impact intercompany eliminations included consolidated balance sheets although primary beneficiary joint venture legal structure joint venture limits recourse creditors general credit assets europe december gilead sciences limited gsl one whollyowned subsidiaries ireland bms entered collaboration arrangement commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories copromote atripla bms also responsible accounting financial reporting tax reporting collaboration december table contents gilead sciences inc notes consolidated financial statementscontinued european commission approved atripla sale european union december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla europe primary responsibility regulatory activities share marketing sales efforts bms major market countries parties agreed provide equivalent sales force efforts revenue cost sharing based relative ratio respective net selling prices truvada efavirenz pari gmbh result acquisition corus pharma inc corus august assumed rights february development agreement corus pari gmbh pari development cayston development inhalation delivery device product terms agreement obligated pay pari services rendered subject achievement specific milestones obligated pay certain milestone payments pari addition make royalty payments based net sales cayston agreement also provided us right reduce royalty rate payable pari november paid pari million reduce royalty rate agreement cayston yet approved commercialization december recorded payment rd expenses consolidated statement income april pursuant february development agreement entered commercialization agreement pari provides supply manufacture inhalation delivery device accessories use cayston terms agreement obligated pay royalties future net sales products pursuant development agreement february received marketing approval fda cayston treatment improve respiratory symptoms cf patients pseudomonas aeruginosa p aeruginosa cayston conditionally approved europe canada september lg life sciences ltd november entered license agreement lg life sciences ltd lgls develop commercialize certain caspase inhibitors treatment fibrotic diseases agreement granted us commercialization rights lglss caspase inhibitors including gs formerly lb terms agreement license worldwide exception korea china india lgls retained rights lgls also retains right develop commercialize caspase inhibitors ophthalmic topical uses worldwide accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement income future alternative use technology agreement also obligated us fund collaborative research program two years identify potential caspase inhibitor drug candidates addition obligated make additional milestone payments million upon achievement certain development regulatory commercial objectives also obligated pay royalties future net sales products developed approved relation collaboration parion sciences inc august entered research collaboration license agreement parion sciences inc parion research develop commercialize certain epithelial sodium channel enac inhibitors treatment pulmonary diseases agreement granted us worldwide commercialization rights gs table contents gilead sciences inc notes consolidated financial statementscontinued formerly p enac inhibitor discovered parion treatment pulmonary diseases including cf chronic obstructive pulmonary disease noncf bronchiectasis accordance terms agreement paid million upfront license fee recorded rd expenses consolidated statement income future alternative use technology made million investment parion form convertible debt recorded noncurrent assets consolidated balance sheet collaboration agreement lead development commercialization activities provide funding full time equivalent employees certain research activities addition obligated make additional payments upon achievement certain milestones pay royalties future net sales products developed approved relation collaboration roche september entered development license agreement agreement roche develop commercialize therapies treat prevent viral influenza tamiflu antiviral oral formulation treatment prevention influenza codeveloped us roche agreement roche exclusive right manufacture sell tamiflu worldwide subject obligation pay us percentage net revenues roche generates tamiflu sales turn subject reduction certain defined manufacturing costs november entered first amendment supplement agreement roche amended agreement provided formation joint manufacturing committee review roches manufacturing capacity tamiflu global plans manufacturing tamiflu us commercial committee evaluate commercial plans strategies tamiflu united states joint supervisory committee evaluate roches overall commercial plans tamiflu global basis case consisting representatives roche us amended agreement also option provide specialized sales force supplement roches marketing efforts united states tamiflu royalties payable us net sales tamiflu sold roche remain amended agreement follows first million worldwide net sales given calendar year b next million worldwide net sales calendar year c worldwide net sales excess million calendar year amended agreement revised provision agreement relating calculation royalty payments given calendar quarter roche pay royalties based actual royalty rates applicable quarter addition amended agreement royalties payable roche us longer subject cost goods sold adjustment provided agreement recorded total million million million tamiflu royalties respectively result acquisition cv therapeutics april assumed rights agreement cv therapeutics roche exclusive worldwide license ranexa license agreement paid initial license fee obligated make certain payments roche upon receipt first second product approvals ranexa following major market countries france germany italy united states united kingdom january received fda approval ranexa treatment chronic angina paid million roche accordance agreement july received marketing authorization european medicines agency emea ranexa treatment chronic angina european union member states paid million roche related approval amount capitalized noncurrent asset consolidated balance sheet amortized useful patent life approximately years expiring september table contents gilead sciences inc notes consolidated financial statementscontinued june entered amendment agreement roche related ranexa amendment provided us exclusive worldwide commercial rights ranexa potential indications humans terms amendment made upfront payment roche obligated make royalty payments roche worldwide net product sales licensed products addition obligated make additional milestone payments upon achievement certain regulatory approvals japan tobacco inc march japan tobacco inc japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor known gs countries world excluding japan japan tobacco retained rights terms agreement incurred front license fee million included rd expenses future alternative use technology march recorded million rd expenses related milestone incurred result dosing first patient phase clinical study july recorded million rd expenses related milestone paid related dosing first patient phase clinical study obligated make additional payments upon achievement milestones well pay royalties future product sales arising collaboration glaxosmithkline inc april granted gsk right commercialize hepsera oral antiviral treatment chronic hepatitis b asia latin america certain territories agreement retained rights hepsera united states canada europe australia new zealand turkey gsk received exclusive rights develop hepsera solely treatment chronic hepatitis b territories significant include china japan south korea taiwan gsk full responsibility development commercialization hepsera territories terms agreement received upfront license payment million received aggregate million milestone payments related commercial approvals hepsera various countries received aggregate million milestone payments gsk achievement gsk four consecutive quarters hepsera gross sales exceeding million achievement certain drug status china upfront license fee milestone payments recorded deferred revenue total million million amortized contract revenue respectively first quarter terminated supply agreement gsk allow gsk assume manufacturing supply obligations hepsera use gsk territories result termination supply agreement recognized remaining million balance deferred revenue contract revenue march terms agreement gsk also required pay us royalties net sales gsk generates sales hepsera epivirhbvzeffix gsks hepatitis product gsk territories recorded million million million royalty revenues respectively november entered agreement gsk commercialize viread treatment chronic hepatitis b five countries asia agreement retain exclusive rights commercialization viread chronic hepatitis b hong kong singapore south korea taiwan china gsk exclusive commercialization rights viread chronic hepatitis b company pay royalties sales viread chronic hepatitis b respective asian territories result acquisition myogen inc myogen november assumed rights march license distribution supply agreements myogen gsk terms license agreement sublicensed gsk exclusive rights market ambrisentan active pharmaceutical ingredient letairis marketed name volibris territories outside united states table contents gilead sciences inc notes consolidated financial statementscontinued pah territories outside united states received upfront payment million subject achievement specific milestones eligible receive total additional milestone payments million addition receive royalties based net sales volibris gsk territories gsk option negotiate us exclusive sublicense additional therapeutic uses volibris gsk territories term license agreement continue conduct bear expense clinical development activities believe required obtain maintain regulatory approvals letairis volibris united states canada european economic area party may conduct additional development activities territories expense parties may agree jointly develop ambrisentan new indications licensed field party pay share external costs associated joint development received milestone payment million gsk validation emea marketing authorization application volibris received million milestone payment related european commission marketing authorization approval volibris milestone upfront license payments recorded deferred revenue amortized contract revenue remaining period performance obligations agreement approximately six years amortized million million million contract revenue respectively menarini international operations luxembourg sa result acquisition cv therapeutics april assumed rights september license agreement cv therapeutics menarini granted menarini exclusive rights ranexa european union specified countries consideration including upfront payment million licensed territory encompasses countries including member states european union russia member states commonwealth independent states select countries central south america term agreement expires countrybycountry basis upon later occur ten years first commercial sale date ranexa country expiration last valid claim licensed patents covering ranolazine country addition menarini may make additional payments investments commercial development milestones promotional detailing commitments commercial milestones primarily related achievement certain sales levels development milestones related approval ranexa europe certain additional indications jointly developed agreement provides mechanisms parties collaborate share costs joint development programs ranexa menarini elects participate also entitled receive royalties sales ranexa territories covered agreement astellas us llc astellas pharma us inc astellas applicable result acquisition cv therapeutics april assumed rights july collaboration agreement cv therapeutics astellas us llc develop market second generation pharmacologic mpi stress agents agreement astellas received exclusive north american rights lexiscan backup compound april received fda approval lexiscan use pharmacologic stress agent mpi studies patients unable undergo adequate exercise stress terms agreement product marketed astellas launched june united states year ended december recognized million royalty revenue astellas related sales lexiscan since agreement astellas pharma us inc related rights market ambisome terms agreement astellas responsible promotion ambisome united states canada exclusive marketing rights ambisome rest world subject table contents gilead sciences inc notes consolidated financial statementscontinued obligation pay royalties astellas connection sales significant markets asia receive royalties astellas sales ambisome unites states canada connection agreement recorded royalty revenues million million million respectively tibotec pharmaceuticals july entered license collaboration agreement tibotec pharmaceuticals tibotec whollyowned subsidiary johnson johnson develop commercialize fixeddose combination truvada tibotecs nonnucleoside reverse transcriptase inhibitor tmc mg rilpivirine hydrochloride currently phase clinical trials agreement tibotec granted us exclusive license combination product administration adults daily oral dosage form worldwide excluding developing world countries japan neither party restricted combining drug products drugs accordance terms agreement reimburse million approximately million development costs incurred tibotec tmc december required use commercially reasonable efforts develop formulate combination product including completion bioequivalence studies year ended december recorded million reimbursable rd expenses incurred tibotec development tmc tibotec required use commercially reasonable efforts develop tmc obtain approval united states europe manufacture combination product assume lead role registration distribution subject regulatory approval commercialization combination product licensed countries tibotec right detail combination product licensed countries option request distributor combination product limited number countries price combination product expected sum price truvada price tmc purchased separately expect recognize product sales revenue future sales combination product approved cost tmc purchased us tibotec combination product approximate market price tmc less specified percentage thirty percent longterm obligations convertible senior notes april issued million principal amount convertible senior notes due million principal amount convertible senior notes due private placement pursuant rule securities act amended notes notes issued par bear interest rates respectively debt issuance costs million connection issuance notes recorded noncurrent assets amortized interest expense straightline basis contractual terms notes notes may convertible common stock based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may convertible common stock based initial conversion rate shares per principal amount notes represents initial conversion price approximately per share notes may converted subject adjustment following circumstances calendar quarter beginning september closing price common stock least trading days last consecutive trading day period previous quarter applicable conversion price per share make specified distributions holders common stock specified corporate transactions occur last month prior maturity applicable notes upon conversion holder would table contents gilead sciences inc notes consolidated financial statementscontinued receive amount cash equal lesser principal amount note ii conversion value note conversion value exceeds may also deliver option cash common stock combination cash common stock conversion value excess notes converted connection change control may required provide make whole premium form increase conversion rate subject stated maximum amount addition event change control holders may require us purchase portion notes purchase price equal principal amount notes plus accrued unpaid interest thereon result adopting guidance relating notes bifurcated conversion option notes debt instrument classified conversion option equity accreting resulting debt discount interest expense following table summarizes information equity liability components notes thousands december carrying amount equity component net carrying amount liability component unamortized discount liability component total interest expense recognized notes million million million years ended december respectively december effective interest rate liability component notes respectively notes converted december ifconverted value would exceed principal amounts notes notes million million respectively concurrent issuance notes purchased convertible note hedges private transactions cost million cover subject customary antidilution adjustments million shares common stock strike prices correspond initial conversion prices notes market value per share common stock time conversion notes strike price applicable convertible note hedges entitled receive counterparties transactions cash shares common stock combination cash common stock option excess market price common stock strike price convertible note hedges convertible note hedges terminate upon maturity related notes none related notes remain outstanding due conversion otherwise also sold warrants acquire million shares common stock subject customary antidilution adjustments private transactions received net proceeds million market value common stock time exercise applicable warrants exceeds respective strike prices required net settle cash shares common stock option respective counterparties value warrants excess warrant strike prices maximum number shares common stock could issued us choose net share settle warrants million shares underlying share amount reserved potential future issuance warrants strike prices per share warrants expiring per share warrants expiring exercisable respective expiration dates taken together convertible note hedges warrants intended reduce potential dilution upon future conversions notes effectively increasing initial conversion price per share notes per share notes net cost million convertible note hedges warrant transactions recorded stockholders equity choice settling convertible note hedges warrants cash shares stock contracts meet applicable criteria equity classification cost convertible table contents gilead sciences inc notes consolidated financial statementscontinued note hedges net proceeds sale warrants classified stockholders equity addition contracts classified stockholders equity indexed common stock accounted derivatives also recorded deferred tax asset million apic effect future tax benefits related convertible note hedges contemporaneously closing sale notes portion net proceeds notes issuance proceeds warrant transactions used repurchase million shares common stock million stock repurchase program terms notes agreements require us comply certain covenants december compliance covenants result cv therapeutics acquisition assumed certain convertible notes cv therapeutics see note december substantially convertible notes extinguished credit facility december entered agreement syndicate banks five year million senior credit facility million facility consisted uncollateralized million term loan entered gilead biopharmaceutics ireland corporation gbic one whollyowned irish subsidiaries uncollateralized million revolving credit facility entered us parent company gilead sciences inc proceeds term loan used gbic december facilitate cash dividend distribution million us parent company part repatriation qualified foreign earnings provisions american jobs creation act ajca year ended december repaid million represented remaining amounts due term loan time term loan terminated terms revolving credit facility entered december interest accrued payable rate libor plus tiered contractual rate basis points payable quarterly arrears us parent company could prepay outstanding borrowings together accrued interest prepaid principal time whole part without penalty premium outstanding interest principal december would payable demand capacity revolving credit facility would increase maximum million term loan repaid ability irrevocably cancel unutilized portion revolving credit facility whole part proceeds obtained revolving credit facility expected used working capital capital expenditures general corporate purposes including issuance letters credit million one whollyowned subsidiaries guarantor december along gbic entered amended restated credit agreement superseded existing revolving credit agreement syndicate banks increase credit facility billion credit agreement also includes subfacility swingline loans letters credit loans credit agreement bear interest either libor plus margin ranging basis points basis points base rate described credit agreement may reduce commitments may prepay loans credit agreement whole part without penalty subject certain conditions credit agreement terminate amounts owing thereunder shall due payable december connection credit agreement us parent company entered agreement guaranteeing obligations gbic credit agreement april connection acquisition cv therapeutics borrowed million credit agreement partially fund acquisition december repaid million credit agreement expect use table contents gilead sciences inc notes consolidated financial statementscontinued proceeds loans credit agreement working capital requirements general corporate purposes december million letters credit outstanding credit agreement required comply certain covenants credit agreement december compliance covenants commitments contingencies lease arrangements entered various longterm noncancelable operating leases equipment facilities lease facilities foster city palo alto san dimas california durham north carolina boulder westminster colorado seattle washington dublin area ireland london area united kingdom also operating leases sales marketing administrative facilities europe canada australia leases expire various dates leases ireland united kingdom years respectively rent subject increase fifth anniversary respective commencement dates many facility leases options renew also leases three corporate aircraft varying terms renewal options upon expiration lease terms lease expense operating leases approximately million million million years ended december respectively aggregate noncancelable future minimum rental payments operating leases follows thousands thereafter legal proceedings may united states district court northern district california executed orders dismissing entirety prejudice fourth consolidated amended complaint associated putative class action lawsuit company six current former executivesour chairman chief executive officer president chief operating officer former executive vice president operations executive vice president research development chief scientific officer senior vice president manufacturing senior vice president researchalleging defendants violated federal securities laws specifically sections b securities exchange act amended rule b promulgated sec making certain alleged false misleading statements plaintiffs appealed dismissal august united states court appeals ninth circuit reversed district courts decision remanded case district court february filed petition writ certiorari supreme court united states requesting court review judgment court appeals april supreme court denied petition case continues district court february filed motion dismiss fourth consolidated amended complaint alternative grounds june district court granted part denied part motion dismiss gave plaintiffs leave amend complaint july plaintiffs filed fifth consolidated amended complaint filed motion dismiss fifth consolidated amended complaint district court heard october order dated october court granted part denied part motion table contents gilead sciences inc notes consolidated financial statementscontinued dismiss respect section b claim court denied motion gilead two six individual defendants court granted motion four individual defendants section claim court denied motion individual defendants therefore defendants remain case november filed answer fifth consolidated amended complaint court scheduled case management conference may possible predict outcome case amounts accrued related outcome case august received subpoena office inspector general us department health human services requesting documents regarding development marketing sales ranexa cooperating continue cooperate related governmental inquiry possible predict outcome inquiry amounts accrued related outcome inquiry also party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments related active pharmaceutical ingredients certain inventory related items december commitments next four years approximately million million million million amounts related active pharmaceutical ingredients represent minimum purchase requirements actual payments purchases related active pharmaceutical ingredients billion billion million years ended december respectively terminated prior agreements purchase three aircraft constructed delivery stockholders equity stock repurchase programs march board directors board authorized program repurchase common stock amount billion twoyear period open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements april repurchased retired shares common stock per share aggregate purchase price million may june repurchased retired aggregate shares common stock average purchase price per share aggregate purchase price million stock repurchase program expired march october board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires december repurchased retired shares common stock per share aggregate million billion stock repurchase program table contents gilead sciences inc notes consolidated financial statementscontinued february entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million financial institution settle initial purchase transaction received shares common stock price per share june upon maturity agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weighted average prices common stock specified period less predetermined discount per share result average purchase price common stock accelerated share repurchase per share accounted accelerated share repurchase two separate transactions shares common stock acquired treasury stock transaction recorded transaction date b forward contract indexed common stock accounted shares received repurchase common stock retired shares immediately net income per share purposes additional shares received upon maturity contract june also recorded stockholders equity determined forward contract indexed common stock met applicable criteria equity classification therefore contract accounted derivative october entered accelerated share repurchase agreement financial institution repurchase million common stock accelerated basis terms accelerated share repurchase agreement paid million settle initial purchase transaction received shares common stock initial price per share march upon termination agreement accordance share delivery provisions agreement received additional shares common stock based average daily volume weightedaverage prices common stock specified period less predetermined discount per share result total number shares repurchased retired accelerated share repurchase agreement shares average purchase price per share accounting accelerated share repurchase consistent previous accelerated share repurchase addition common stock repurchased two accelerated share repurchase transactions repurchased retired shares common stock average purchase price per share aggregate purchase price million open market transactions addition additional shares received accelerated share repurchase agreement completed march repurchased retired shares common stock average purchase price per share aggregate purchase price million open market transactions december completed share repurchases billion stock repurchase program use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings result stock repurchases reduced common stock apic aggregate million charged million retained earnings result stock repurchases reduced common stock apic aggregate million charged billion retained earnings result stock repurchases reduced common stock apic aggregate million charged million retained earnings january board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans table contents gilead sciences inc notes consolidated financial statementscontinued privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires january preferred stock shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series designated shares series junior participating preferred stock potential issuance november rights agreement bny mellon investor services llc formerly known chasemellon shareholder services llc amended rights plan preferred stock outstanding december rights plan rights plan provides distribution preferred stock purchase right dividend share common stock purchase rights currently exercisable certain conditions involving acquisition proposed acquisition person group common stock purchase rights permit holders holder purchase common stock discount market price time upon payment specified exercise price per purchase right addition event certain business combinations purchase rights permit purchase common stock acquirer discount market price time certain conditions purchase rights may redeemed board whole part price per purchase right purchase rights voting privileges attached automatically trade common stock october october may board approved amendments rights plan first amendment provided among things increase exercise price right plan extension term plan november october second amendment provides among things increase exercise price right plan extension term rights plan october third amendment clarifying amendment entered connection increase designated number shares series junior participating preferred stock potential issuance rights plan may stock option plans may stockholders approved adopted gilead sciences inc equity incentive plan plan stock options nexstar pharmaceuticals inc nexstar triangle pharmaceuticals inc triangle corus myogen cv therapeutics stock option plans assumed result acquisitions nexstar triangle corus myogen cv therapeutics converted options purchase common stock effective closing respective acquisitions plan broad based incentive plan allows awards granted employees directors consultants plan provides option grants designated either nonqualified incentive stock options prior january granted non qualified incentive stock options stock options granted january nonqualified stock options plan employee stock options generally vest five years exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares may stockholders approved amendment plan increase number shares authorized issuance plan shares common stock table contents gilead sciences inc notes consolidated financial statementscontinued connection acquisition cv therapeutics assumed cv therapeutics equity incentive plan amended restated nonemployee directors stock option plan amended restated equity incentive plan amended restated nonstatutory incentive plan amended restated employee commencement incentive plan amended restated collectively cv therapeutics plans majority options issued outstanding cv therapeutics plans april converted options purchase approximately million shares common stock remain subject original terms conditions shares available future grant cv therapeutics plans december total shares common stock authorized grant shares remain available future grant plan following table summarizes activity stock option plans option grants presented table exercise prices less fair value underlying common stock grant date shares thousands year ended december weighted weighted weighted average average average shares exercise price shares exercise price shares exercise price outstanding beginning year granted assumed forfeited expired exercised outstanding end year exercisable end year weightedaverage grant date fair value options granted year total intrinsic value options exercised years ended december million million million respectively total fair value stock options vested years ended december million million million respectively december number options outstanding expected vest net estimated future option forfeitures weightedaverage exercise price per share aggregate intrinsic value million weightedaverage remaining contractual life years aggregate intrinsic value stock options outstanding stock options exercisable december billion billion respectively december weightedaverage remaining contractual life options outstanding options exercisable years respectively december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years table contents gilead sciences inc notes consolidated financial statementscontinued performance shares restricted stock awards january granted performancebased share awards performance shares plan awards divided three tranches vesting performance measurement purposes subject achievement specified market performance goals relative predetermined peer group awards vest threeyear period actual number shares common stock ultimately issue calculated multiplying number performance shares payout percentage ranging performance shares vest committee subcommittee board determined achieved specified market performance goals fair value performance shares estimated grant date using monte carlo valuation methodology stockbased compensation expenses performance shares recognized requisite service periods using straightline expense attribution approach reduced forfeitures weightedaverage grant date fair value performance shares per share january granted performancebased share awards performance shares performance shares respectively terms substantially similar performance shares except single threeyear performance measurement vesting period performance shares performance shares weightedaverage grant date fair value performance shares performance shares per share respectively performance shares recognized million million million stockbased compensation expenses respectively relating performance shares granted timebased restricted stock awards employees plan awards vest annually fiveyear period recognized million stockbased compensation expenses relating timebased awards also granted performancebased restricted stock awards certain employees plan vesting awards subject achievement specified performance goals number awards issued date significant employee stock purchase plan employee stock purchase plan amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers twoyear lookback feature well automatic reset feature provides offering period reset new lower priced offering offering price new offering period less current offering period espp purchases settled common stock espps previously authorized available pool shares shares issued espp million total shares common stock reserved issuance espp shares available issuance espp december december million unrecognized compensation cost related espp expected recognized estimated weightedaverage period years table contents gilead sciences inc notes consolidated financial statementscontinued stockbased compensation following table summarizes stockbased compensation expenses included consolidated statements income thousands year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense included net income years ended december capitalized million million million stockbased compensation costs inventory respectively stockbased compensation recognized expense requisite service periods consolidated statements income using graded vesting expense attribution approach nonvested stock options granted prior january using straightline expense attribution approach stock options granted adoption new guidance sharebased payments employees directors january stockbased compensation expenses related stock options recognized adoption new guidance based awards ultimately expected vest gross expense reduced estimated forfeitures guidance requires forfeitures estimated time grant revised necessary subsequent periods actual forfeitures differ estimates estimated forfeitures based historical experience prior adoption guidance pro forma information required disclosed included forfeitures occurred result guidance adopted january recognize tax benefit stockbased compensation apic incremental tax benefit realized tax attributes currently available us utilized addition elected account indirect benefits stockbased compensation research tax credit extraterritorial income deduction consolidated statements income rather apic table contents gilead sciences inc notes consolidated financial statementscontinued valuation assumptions fair values awards granted stock option plans espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts comprehensive income loss comprehensive income loss comprises net income certain changes stockholders equity excluded net income changes fair value outstanding effective cash flow hedges changes unrealized gains losses availableforsale securities changes cumulative foreign currency translation account comprehensive income loss years ended december included consolidated statements stockholders equity components comprehensive income loss shown net related taxes underlying assets liabilities held jurisdictions expected generate future tax benefit liability table contents gilead sciences inc notes consolidated financial statementscontinued following reclassifications recorded connection net realized gains losses sales securities cash flow hedges previously included comprehensive income loss thousands year ended december net unrealized gain loss related availableforsale securities net tax impact respectively net unrealized gain loss related cash flow hedges net tax impact respectively reclassification adjustments related cash flow hedges net tax impact respectively comprehensive income loss balance accumulated comprehensive income loss net taxes reported consolidated balance sheets consists following components thousands december net unrealized gain loss availableforsale securities net unrealized gain loss cash flow hedges cumulative foreign currency translation adjustment accumulated comprehensive income loss disclosures segments enterprise related information operate one business segment primarily focuses development commercialization human therapeutics life threatening diseases products included one segment major products truvada atripla viread hepsera ambisome together accounted substantially total product sales years ended december similar economic characteristics including nature products production processes type customers distribution methods regulatory environment table contents gilead sciences inc notes consolidated financial statementscontinued product sales consist following thousands year ended december antiviral products truvada atripla viread hepsera emtriva total antiviral products ambisome letairis ranexa total product sales following table summarizes total revenues external customers collaboration partners geographic region thousands product sales productrelated contract revenue attributed countries based shipto location royalty nonproduct related contract revenue attributed countries based location collaboration partner year ended december united states outside united states france spain united kingdom italy germany switzerland european countries countries total revenues outside united states total revenues december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment december net book value property plant equipment united states ireland canada million million million respectively comprised approximately total net book value property plant equipment table contents gilead sciences inc notes consolidated financial statementscontinued following table summarizes revenues customers individually accounted total revenues total revenues year ended december cardinal health inc mckesson corp amerisourcebergen corp income taxes provision income taxes consists following thousands year ended december federal current deferred state current deferred foreign current deferred provision income taxes foreign pretax income billion billion billion years ended december respectively cumulative unremitted foreign earnings considered permanently invested outside united states us taxes provided approximately billion billion december respectively residual us tax liability amounts remitted would approximately billion billion december respectively difference provision income taxes amount computed applying us federal statutory income tax rate income provision income taxes follows thousands year ended december income provision income taxes tax federal statutory rate state taxes net federal benefit foreign earnings different rates research credits net unbenefitted stock compensation provision income taxes table contents gilead sciences inc notes consolidated financial statementscontinued deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows thousands deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards capitalized intangibles net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles unremitted foreign earnings total deferred tax liabilities net deferred tax assets valuation allowance increased decreased million million million years ended december respectively april acquisition cv therapeutics established valuation allowance million deferred tax asset related california state net operating loss carryforwards december upon integration cv therapeutics concluded likely realize benefit deferred tax assets related certain state net operating loss carryforwards therefore released related valuation allowance resulting income tax benefit approximately million december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses nols credits utilization file federal state foreign income tax returns many jurisdictions united states abroad federal income tax purposes statute limitations open onward certain acquired entities statute limitations open years inception due utilization nols credits carried prior years california income tax purposes statute limitations remains open years table contents gilead sciences inc notes consolidated financial statementscontinued income tax returns audited federal state foreign tax authorities currently examination internal revenue service irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions december total federal state foreign unrecognized tax benefits million million respectively including interest million million respectively total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition continued classify interest penalties related unrecognized tax benefits part income tax provision consolidated statements income reached agreement irs several issues related examinations federal income tax returns also amended california income tax returns based resolution certain tax positions irs result reduced unrecognized tax benefits million december believe reasonably possible unrecognized tax benefits decrease approximately million next months expect clarification irs tax authorities around certain uncertain tax positions respect remaining unrecognized tax benefits currently unable make reasonable estimate period cash settlement respective tax authorities following rollforward total gross unrecognized tax benefit liabilities years ended december thousands balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period deferred compensation plans maintain retirement savings plan eligible employees may defer compensation income tax purposes section k internal revenue code gilead plan gilead plan employees may contribute eligible annual compensation subject irs plan limits make matching contributions gilead plan contributed employees contributions annual maximum match contributed employees first contributions annual maximum match total matching contribution expense table contents gilead sciences inc notes consolidated financial statementscontinued gilead plan years ended december million million million respectively maintain deferred compensation plan directors key employees may defer compensation income tax purposes deferred compensation plan nonqualified deferred compensation plan subject qualification requirements section internal revenue code compensation deferred december subject requirements section internal revenue code plan officers senior grade level employees may contribute annual salaries annual bonus directors may contribute annual retainer fee amounts deferred participants deposited rabbi trust recorded noncurrent assets consolidated balance sheets beginning directors may also elect receive portion annual cash retainer phantom shares gives participant right receive amount equal value specified number shares specified period time payable shares common stock fractional shares paid cash established plan administrator december phantom shares outstanding participants elect one several distribution dates available plan receive deferred compensation payment subsequent events january board authorized new program repurchase common stock amount billion open market private block transactions pursuant rule b plans privately negotiated purchases means including accelerated stock repurchase transactions similar arrangements repurchase plan expires january february received marketing approval fda cayston treatment improve respiratory symptoms cf patients p aeruginosa table contents gilead sciences inc notes consolidated financial statementscontinued quarterly results operations unaudited following amounts thousands except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholdersbasic net income per share attributable gilead common stockholdersdiluted second quarter recognized million charge purchased iprd associated acquisition assets navitas related cicletanine business january adopted guidance notes notes retrospective basis guidance required us bifurcate conversion option debt instrument classifying conversion option equity accreting resulting discount debt additional interest expense expected life debt see note january adopted guidance joint ventures bms retrospective basis result adopting guidance presented noncontrolling interest consolidated statements income net loss attributable noncontrolling interest component consolidated net income retrospective basis see note table contents gilead sciences inc schedule ii valuation qualifying accounts balance additions balance beginning charged end period expense deductions period year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets year ended december accounts receivable allowances valuation allowance deferred tax assets allowances doubtful accounts sales returns cash discounts chargebacks valuation allowance deferred tax assets includes million million december respectively related acquisitions table contents